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Abstract 
Penetrating traumatic brain injury (pTBI) causes significant neural damage and debilitation. 
The management of pTBI is largely supportive currently, with no clinically established 
regenerative therapies. Researchers have previously evaluated the regenerative potential of 
biomaterial constructs called hydrogels in pTBI. To screen biomaterials for regenerative 
application, clinically predictive models of pTBI are required. However, there is a lack of 
facile, high throughput, pathomimetic in vitro pTBI models capable of evaluating biomaterial 
implantation. 
This thesis aimed to develop methods to i) establish a high throughput and facile culture 
system containing the major glial cell types, which play an important role in biomaterial 
handling in the central nervous system ii) introduce reliable and characterizable penetrating 
lesions into the cultures iii) implant DuraGen PlusTM – an Food and Drug Administration 
(FDA) approved neurosurgical grade biomaterial into the lesion iv) visualize cell-biomaterial 
interactions using simple light microscopy v) refine the model to establish a high throughput 
neuronal model containing all of the neural cell types. 
The findings of this study show that the key pathological features of injury seen in pTBI can 
be reliably replicated, in this novel, facile, high throughput, multi-glial model. Specifically, 
peri-lesional astrocytes have markedly different responses to injury versus distal astrocytes 
showing hypertrophic palisading astrocytes and glial fibrillary acidic protein (GFAP) 
upregulation analogous to reactive astrogliosis in vivo. In addition, microglia and 
oligodendrocyte precursor cells (OPCs) were observed to infiltrate the lesion core similar to 
processes seen in pTBI models in vivo. Furthermore, DuraGen PlusTM could be implanted 
into the lesions to visualize cell-biomaterial interactions. Finally, early pilot data shows that 
use of an alternative chemical medium can further support the growth of neurons, resulting in 
a model containing all neural cell types in a technically simple and high throughput 
experimental system.  
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Chapter 1 
General introduction 
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1.1.1 Epidemiology of traumatic brain injury 
Globally, traumatic brain injury (TBI), affects around 10 million people annually, with around 
1.7 million cases of TBI occurring within the United States (US) (1,2). The mortality rate for 
TBI is 30 per 100,000 or an estimated 50,000 deaths in the US. Within the US, TBI is the 
leading cause of death in individuals under 44 (3). In 2014, 56,800 people died from TBI-
related deaths; 2,529 deaths were among children. In the US, the total annual direct cost of 
TBI management is estimated at $48 billion dollars, whilst the indirect costs such as 
productivity losses is estimated at $56 billion US dollars (2).  
1.1.2 The classification of TBI 
TBI can broadly be classified by two distinct aetiologies; closed TBI or penetrating TBI (pTBI) 
(4). Closed TBI results from an injury to the head without dural breach, often by a blunt 
object. pTBI results from an object possessing enough energy to pierce the skin, skull, dura 
and enter the brain (5). TBI aetiology is multifactorial, however falls and being struck with or 
against an object represents most cases (figure 1). 
  
Figure 1: Infographic representing the causes of TBI (6) 
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pTBI is the most lethal form of TBI, with approximately 70-90% of patients dying prior to 
hospital admission and 50% of those whom reach the hospital die during resuscitation in the 
emergency department (7). pTBI survivors are a minority and given that these patients often 
have to live with severe debilitation, this review will focus on pTBI including the aetiology, 
pathophysiology and management of this pathology (8). pTBI is prevalent in many different 
populations, particularly civilians living in areas with a high incidence of violence, and military 
personnel (8). Of the 333,169 US military TBI deaths recorded between 2000 -2015, 4,904 
were classified as pTBI (7). Furthermore, 32,000 -35,000 civilian deaths in the US are as a 
result of pTBI (7). pTBI can result from any object which breaches the dura and enters the 
brain. Unsurprisingly, gunshots are the most common cause of pTBI (9). However, wounds 
induced from knives, nails, screwdrivers and ballpoint pens have also been described (10). In 
addition, within military populations shrapnel from improvised explosive devices also cause 
pTBI (11).  
1.1.3 pTBI causes severe tissue damage 
The clinical quantification of the severity of TBI is often carried out using scales such as the 
Glasgow Coma Scale (GCS) seen in table 1 (12). 
 
Table 1: Different components assessed in the Glasgow coma scale (13) 
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The GCS categorizes TBI in three distinct categories; mild, moderate and severe (14). Mild 
TBI represents 75-85% of all TBI and is most often seen in the context of closed TBI. In 
addition, mild TBI is the most common TBI affecting military personnel, and has been 
reported to affect around 15.2% to 22.8% of returning service members (12). Branded as the 
“silent epidemic” mild TBI is characterized with a GCS of 13-15 and presents typically with 
subtle concussive symptoms, including memory and cognitive impairments (15). Although 
patients with mild TBI make a complete neurological recovery, up to 30% suffer with 
prolonged behavioural changes. Patients with moderate TBI have a GCS of 9-13. Indeed, 
pTBI almost always presents as severe TBI. Here, patients have a GCS of 3-8 and it is often 
characterized by a prolonged loss of consciousness, inability to speak and open the eyes 
and unresponsiveness to commands (16). Lower GCS scores typically correlate with a poor 
prognosis (17).  
1.1.4 pTBI management is supportive and lacks regenerative treatments 
pTBI is a neurosurgical emergency until proven otherwise (18). The management can be 
described in two distinct phases; acute stage management and secondary rehabilitative 
management. Patients should initially be assessed according to current Advanced Trauma 
Life Support (ATLS) guidelines and be subjected to a full A-E (airway, breathing, circulation, 
disability, exposure) approach and undergo primary resuscitation (19). Post-resuscitative 
GCS scores should also be obtained, and if a score less than 8 is achieved the patient must 
be intubated (20).  
Computerized Tomography (CT) scans are the neuroimaging gold standard, providing key 
information which guides subsequent management (21). Current acute management 
strategies are largely supportive and involve intracranial pressure (ICP) monitoring and 
aggressive early surgical wound debridement with or without decompressive 
craniotomy/craniectomy and closure of the dura to form a watertight seal (22). Together, 
these measures have shown to improve prognosis as they limit cerebral oedema and post-
trauma infection (11). Specifically, the bacterium Staphylococcus aureus is the most common 
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cause of infection (23). The increased risk of infection can be attributed to a variety of 
factors; firstly, penetration of the brain including the skin, skull and meninges breaches the 
normal “brain sterility” and exposes the brain to external pathogens. Secondly, the 
penetrating foreign objects are unsterile and thus carry an intrinsic risk of infection. Thirdly, 
hair, bone fragments and cerebrospinal fluid (CSF) leaks within the brain pose a potential 
risk of infection (3). Thus, early broad-spectrum prophylactic antibiotics are often 
administered in addition to surgical wound debridement. In addition to infection, the presence 
of necrotic brain tissue and foreign bodies are sometimes associated with post-traumatic 
epileptic seizures, thus anti-seizure drugs also form a part of the management (24). To 
promote long term recovery, patients are also managed from a biopsychosocial approach 
and patient rehabilitation involves many members of the multidisciplinary team; 
neurosurgeons, neurologists, nurses, physiotherapists, psychiatrists, speech and 
occupational therapists (25).  
Currently, as discussed above, pTBI management is largely supportive, with no clinically 
established regenerative therapies. Thus, the development of such regenerative therapies is 
of paramount importance. However, to understand how regenerative therapies could 
potentially help pTBI patients one must first have an awareness of why regeneration is 
limited within the CNS. 
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1.2.1 The central nervous system has a limited capacity for repair 
The central nervous system (CNS) is unique among physiological tissues in that it has an 
intrinsically low regenerative capacity (26). Limited CNS regeneration is multifactorial 
including; limited regenerative capacity of adult neurons, scarring, inflammation and inhibitory 
chondroitin sulphate proteoglycans (CPSGs) (27). 
1.2.2 Myelin-associated inhibitors are a barrier to repair 
One theory as to why the CNS environment is inhibitory is due to the presence of myelin-
associated inhibitors (MAIs). 
 Firstly, injury in the CNS and axonal damage increases the presence of the myelin 
breakdown products, which are in themselves inhibitory. Three main inhibitors within myelin 
have been identified; neurite outgrowth inhibitors (NOGO), myelin-associated glycoprotein 
(MAG) and oligodendrocyte myelin glycoprotein (OMGP) (27). These molecules have been 
shown to be the main inhibitors to regeneration early in injury, prior to the maturation of the 
glial scar.  
NOGO-A is the most common isoform of NOGO, a transmembrane protein expressed by 
oligodendrocytes (28). Studies have demonstrated the inhibitory actions of NOGO, by 
studying NOGO-A knockout mice. Interestingly, NOGO knockout mice have reduced 
inhibitory effects on neurite outgrowth in vitro (27). 
MAG is a transmembrane glycoprotein produced by oligodendrocytes, although MAG is also 
found in the peripheral nervous system (PNS). Normally MAG plays a key role in neuronal 
development by promoting axon growth in young neurons, whilst inhibiting axonal growth in 
mature neurons (26). Furthermore, research has shown a role for maintaining axonal 
integrity in disease states. However, MAG has been shown to limit neurite outgrowth in vitro 
by interacting with the neuronal receptors, nogo66 receptor-1, nogo66 receptor -2, paired 
immunoglobulin-like receptor b and gangliosides (29). Thus, MAG is often considered as 
both a growth promoting and growth inhibitory agent.  
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OMGP is a glycosylphosphatidylinositol (GPI) linked protein produced both by 
oligodendrocytes and neurons. Like MAG, OMGP is also found in the PNS. In vivo studies 
have demonstrated that OMGP has inhibited axonal sprouting post CNS injury (30). 
All three MAIs have been shown to inhibit neurite outgrowth in vitro and are postulated to 
inhibit growth in vivo (27). One well understood mechanism which is common to the MAIs, is 
their interaction with glycosylphosphatidylinositol linked NOGO receptor (NGR). Upon MAI 
interaction with the receptor, NGR activates p75NTR which in turn activates Rho – the main 
mediator of inhibition (29). 
Of relevance to pTBI, the glial scar has been shown to be inhibitory to regeneration in 
several ways. The dense network of hypertrophied reactive astrocytic processes and 
surrounding extracellular matrix (ECM) form a barrier to axonal growth and regeneration (31). 
Huang et al demonstrated that regenerated axons were “pinched” by the glial scar, indicating 
that regeneration must be targeted prior to maturation of the glial scar (32). When 
regenerating axons are unable to complete regeneration, they form dystrophic end bulbs – a 
morphological fate which characterizes regeneration failure.  
Furthermore, astrocytic production of CSPGs has shown to inhibit regeneration both in vitro 
and in vivo (32–34). CSPGs are a family of ECM proteins and consist of a protein core to 
which chondroitin sulphate chains are covalently attached. The chondroitin sulphate chains 
are major inhibitory molecules. Increased production of CSPGs has been demonstrated 
within the glial scar by reactive astrocytes (32). CSPGs are membrane bound yet astrocytes 
can also secrete them into the extracellular space (33). Adult sensory neurons have been 
shown to undergo axonal regeneration when transplanted into the corpus callosum provided 
they are transplanted with minimal trauma to the surrounding tissue (35). Interestingly, when 
there is increased trauma, or indeed a lesion site, regeneration stops as the axons approach 
the lesion as there is a high concentration of CSPGs (34). 
Different theories, as to why CSPGs are inhibitory have been proposed, including CSPGs 
acting as a negatively charged boundary which actively inhibits the growth of regenerating 
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axons (36). Furthermore, there is additional evidence that CSPGs inhibit a variety of growth 
promoting molecules such as fibronectin and L1 (33). Interestingly, like myelin inhibitors 
CSPGs also mediate inhibition through NOGO receptors (32). In addition, receptor tyrosine 
phosphatase is able to bind CSPGs yet also has a role in axonal growth inhibition (37). 
Specifically, two members of the leukocyte common antigen related subfamily of receptor 
tyrosine phosphatases, protein tyrosine phosphatases1/4 and leukocyte common antigen 
related bind CSPGs with high affinity and mediate suppression of axon elongation by 
CSPGs.  
As discussed above, the CNS has an intrinsically limited regenerative capacity. It is important 
to understand however, the key pathophysiological responses to pTBI as it is these 
responses which partially contribute to the hostile and inflammatory environment which can 
be inhibitory to repair. 
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1.3.1 pTBI results in neuroinflammation and glial scarring - both inhibitory to 
repair 
Previous literature has classified both microglia and astrocytes as the two principal 
immunocompetent cell types within the central nervous system (CNS) (38). These cells 
mediate neuroinflammation and the glial scar, two features seen in pTBI (39). Understanding 
these processes requires an understanding of the roles of microglia and astrocytes. 
1.3.2 Microglia are the major immune cell type of the CNS 
Microglia are resident tissue macrophages of the CNS and represent ca 20% of all glia (40). 
Generally, microglia drive and resolve inflammation within the CNS. Microglial role and 
function is largely dependent on the activation state (40,41). 
M0 represents the unactivated microglial activation state, seen under normal physiological 
conditions, typically ramified (figure 2). M1 represents pro-inflammatory microglia typically 
seen in response to CNS insults including tissue damage (42,43). M1 microglia are typically 
described as amoeboid (42,43).   
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Figure 2: A schematic demonstrating the morphological changes ramified microglia 
undergo in response to CNS trauma 
Note how amoeboid microglia are rounded as ramified microglia have undergone process 
retraction. 
 
1.3.3 M0 microglia monitor tissue for damage and infection 
Ramified microglia represent ca 20% of all glial cells within the adult brain parenchyma. With 
regards to their morphology ramified microglia have a high membrane branches : cytoplasm 
ratio (40) (figure 3). 
 
Figure 3: Immunohistochemistry micrograph of a ramified microglial cell which is 
highly processed and displaying classical resting morphology. Scale bar: 10 μm (44). 
CNS insult/trauma 
Ramified microglia 
Amoeboid microglia 
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In healthy tissue, ‘resting’ (M0) microglia are constantly surveying tissue for damage 
associated molecular patterns/ pathogen associated molecular patterns (DAMPS)/(PAMPS) 
(45). Although previously it was considered that resting microglia were inactive, recent 
literature suggests that ramified microglia undertake a variety of functions under resting 
physiological conditions; scanning the surrounding microenvironment for possible insults. 
Zanier et al (2015) suggests that microglia are “never resting” and that ramified microglia 
have a crucial role in not only metabolite removal but also clearing debris and toxic factors 
released as a by-product of neuronal injury (46). In addition, further roles include: to optimize 
neural circuits and maintain neuronal activity through synaptic pruning whilst also optimizing 
conduction through synapses by maintaining neurotransmitter signalling (47).  
1.3.4 M1 inflammatory microglial responses combat infection and clear cellular debris 
Pro-inflammatory responses to trauma/infection results in loss of ramified microglial 
processes and the presence of amoeboid microglia (48). Amoeboid microglia are a highly 
motile, phagocytic cell and thus are morphologically similar to monocytes and macrophages 
(figure 4). 
 
Figure 4: Immunohistochemistry micrograph of a microglial cell showing classical 
signs of M1 activation 
Note the lack of processes and rounded morphology. Scale bar: 10 μm (44). 
 
 
12 
 
Exposure to pro-inflammatory stimuli induces reactive microglia to release pro-inflammatory 
cytokines such as tumour necrosis factor (TNF) alpha, interleukin (IL) 1 beta , and also 
protease enzymes and reactive oxygen species (ROS) (28,45,49–52). Reactive microglia 
primarily phagocytose damaged/apoptotic cells and cellular debris. Although the presence of 
M1 microglia is often seen as a sign of neuroinflammation, the process of M1 microglia 
phagocytosing cellular debris has shown promise in promoting regeneration. This is because 
cellular debris can be toxic and inhibitory to axonal regeneration, thus active phagocytosis 
and subsequent removal of this debris prevents debris mediated inhibition (53). 
 
1.3.5 Is there a role for ‘M2’ microglia in CNS regeneration? 
There is active debate with regards to the presence of M2 microglia, as currently there is 
evidence both for and against the existence of M2 microglia (52). Generally, researchers in 
favour of the M2 classification characterize these microglia as anti-inflammatory. For 
instance, Lively and Schlichter et al (2013), demonstrated that M2 microglia, upregulate 
MRC1(54). MRC1 is a transmembrane pattern recognition receptor which binds 
carbohydrates and is involved in pinocytosis and phagocytosis of immune cells. Specifically, 
microglial MRC1 upregulation has been associated with a neuroprotective microglial 
phenotype (52). M2 microglia are considered to exert an anti-inflammatory effect and be 
conducive to pro-repair as they release type 2 cytokines (transforming growth factor beta and 
IL-10), whilst also inhibiting pro-inflammatory cytokines. Furthermore, specifically IL-4 
alternatively activated M2 microglia are neuroprotective and conducive to regeneration within 
the CNS as they promote both neurogenesis and oligodendrogenesis (55). Miron et al (2013) 
demonstrated that M1 microglia “switch” to M2 microglia during remyelination, 
oligodendrogenesis, which resulted in increased oligodendrocyte differentiation, thus 
providing evidence that M2 microglia may also have a  pro-neuroregenerative role (56)(57).  
Although there is evidence both for and against the M1/M2 microglial classification as 
presented above, more recently researchers have been in favour of a multidimensional 
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concept of microglial/macrophage ontogeny, activation and function (58). Researchers have 
studied the microglial phenotypes in relation to neurodevelopment, homeostasis, ageing, 
neurodegeneration and in vitro conditions through transcriptome studies (58–60). Overlaying 
disease specific microglial signatures has led to the identification of genes which are 
commonly expressed (although in different proportions) across all conditions/environments 
(58–60). These microglial genes have been referred as the microglial core gene signature 
and thus provides strong evidence in favour of microglia as a multidimensional cell type 
versus strict M1 versus M2 classification applying to each condition(58–60).  
1.3.6 Astrocytes are the main homeostatic cells of the CNS 
Astrocytes represent a major glial cell type representing 20%-40% of all glia (61). Astrocytes 
have a key role in the development of the CNS and formation of synapses, as they secrete a 
variety of growth inducing/inhibitory molecules responsible for axon guidance during 
development such as glutamate, adenosine triphosphate, cytokines and other signalling 
molecules such as adenosine and lactate (61). Astrocytes are also involved in 
neurotransmitter metabolism and regulate extracellular pH and potassium (38). Also, 
astrocytes maintain the integrity of the blood-brain barrier (BBB) and blood flow (62). 
Furthermore, during CNS development, astrocytes interact with other glial cell types 
including the microglia. Specifically, neonatal astrocytes cause neurons to upregulate the 
complement protein c1q which is localized selectively to immature synapses, thus phagocytic 
cells such as the microglia can recognize complement proteins and can remove these 
complement tagged cells, thereby clearing unwanted axons and synapses (61).  
1.3.7 Astrocytes are key mediators in neuroinflammation 
Astrocytes have been described as “active players” in neuroinflammation (63). In response to 
the specific inflamed milieu, astrocytes can secrete a variety of cytokines and chemokines, 
whilst also having a role in immune cell activation and migration (41). 
 Much like the M1/M2 microglia classification discussed above; a classification scheme 
applies to astrocytes. Both A1 and A2 reactive astrocytes been described (64). A1 astrocytes 
 
 
14 
 
are inhibitory to repair (64). A2 astrocytes on the other hand are considered to be “pro-
repair”. Unlike microglial activation states, astrocytes are accurately classified according to 
the genes they upregulate. A1 astrocytes upregulate classical complement cascade genes 
whilst A2 astrocytes upregulate neuroprotective genes (61) (64).   
The glial scar is characterized by reactive gliosis (section 1.3.8) and is often seen in 
response to CNS injury and evolves with time (31). Within hours after axonal injury, cellular 
debris such as myelin causes activation and proliferation of microglial cells which 
subsequently migrate into sites of injury (figure 5).  
 
Astrocytes- red cells    Microglia- green cells   OPC- purple cells.  
Lesion core- light blue circle in the middle 
Figure 5: A schematic showing the hallmarks of the glial scar 
Astrocytes are hypertrophic with process polarization towards the lesion core. Astrocytes 
have surrounded the lesion core. Microglia and OPCs infiltrate the lesion core prior to 
astrocytic responses.  
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Oligodendrocyte precursor cells (OPCs) are seen 3-5 days post-injury with or without 
meningeal cells and fibroblasts depending on meningeal damage. Astrocytes can become 
activated as early as 1 day post-lesion and hypertrophy and migrate towards the lesion. 
Astrogliosis is characterized by the presence of reactive astrocytes – hypertrophied 
astrocytes which upregulate a variety of genes and molecules including GFAP, and form a 
glial scar post-acute CNS insult (61). GFAP is a cytoskeletal protein and is used to identify 
astrocytes both in vitro and in vivo (31,37). Specifically, upregulation of GFAP signifies CNS 
injury and trauma (32).  
Anatomically, the glial scar can be divided into two distinct zones. Firstly, the lesion core 
predominately contains NG2 positive glia, fibroblasts/pericytes (perivascular cells that wrap 
around capillaries) and macrophages. The outer layer surrounding the lesion core consists of 
reactive hypertrophic astrocytes with elongated, overlapping processes polarizing towards 
the lesion. The outer layer also consists of increased numbers of activated microglia which 
surround the lesion core (65). 
1.3.8 pTBI results in astrogliosis and microgliosis  
In pTBI, damaged cells release damaged-associated molecular patterns (DAMPS) which 
interact with microglial toll like receptors and subsequently activate them (66). Upon 
activation, microglia enter the lesion site following chemotactic signals, and phagocytose 
cellular debris (42). Furthermore, microglial responses to pTBI can be described in the 
following ways : increased staining intensity of microglial marker Iba1 (45,47,60), increased 
microglial numbers around and inside the lesion due to both microglial proliferation and 
migration at these sites and finally distinct morphological changes from normal resting 
microglia with a ramified morphology to activated and rounded microglia with a more 
amoeboid morphology (39,42,67,68). Also, microglia release inflammatory cytokines and 
chemokines which recruit further microglia and astrocytes (64,69). Specifically, microglial 
release of IL-1 alpha, TNF alpha and complement 1q has shown to activate A1 astrocytes 
which become activated from their resting state (64). Upon injury, resting and processed 
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astrocytes become reactive and hypertrophic. Reactive hypertrophic astrocytes form a 
barrier between damaged and healthy tissue known as the glial scar (62). To effectively form 
the glial scar around the injury track, the astrocytes must “accumulate” around the lesion 
(70). Astrocytic accumulation and recruitment in vivo has been characterized by forming 
elongated processes and polarizing towards the lesion and has been described as palisading 
astrocytes (70,71).  
1.3.9 Neuronal response to pTBI  
Neurons are electrically active cells responsible for the conduction of action potentials within 
the nervous system (72). Neurons have four main distinct regions: cell body, dendrites, axon 
and axon terminals (figure 6). 
 
Figure 6: A schematic showing the anatomy of a neuron (73) 
 
The cell body houses the nucleus and is the site of most of the neuronal protein synthesis. 
Likewise, the presence of lysosomes also makes the cell body the site of neuronal protein 
degradation (74). Axons are responsible for the conduction of action potentials away from the 
cell body. The dendrites allow interneuronal communication as dendrites receive chemical 
signals from axon termini of other neurons (75).  
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Generally, post-injury, most axons within the adult CNS are unable to spontaneously 
regenerate like they do in the peripheral nervous system (PNS), leading to significant 
functional impairment. Interestingly, Aguyao et al demonstrated that CNS axons can 
regenerate within a PNS environment, thus indicating that the PNS environment favours 
repair and that the CNS environment may be inhibitory to repair (76). 
The neuropathological consequences of pTBI are often related to the impact velocity of the 
projectile (77). Low velocity projectiles such as shrapnel, or bullets discharged from a firearm 
with a low muzzle velocity enter the cranium and create a missile track leading to a 
laceration, shearing and compression of the brain along the track (10,77). High velocity 
projectiles include most bullets, where in addition to the missile track, upon impact high 
pressure shock waves transmit through the brain and create an additional temporary 
cavitation effect. The temporary cavity collapses and expands in a wave like pattern, 
compressing the brain against the skull. Each cycle of collapse and expansion is responsible 
for significant tissue damage and has been shown to cause neuronal shear injuries, 
epi/subdural hematomas and parenchymal contusions. Microscopically, widespread axonal 
injury and haemorrhage has been reported to be distributed throughout the cerebral 
hemispheres. Oehmichen et al found that away from the missile track, neurons are arranged 
in a wave like pattern suggesting axonal damage secondary to the temporary cavitation 
effect (11) (78). They microscopically characterized the cell destruction resulting from the 
missile track and found significant shearing of blood vessels, subsequently leading to 
haemorrhagic extravasation adjacent to the track (78) (figure 7). 
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Figure 7: A schematic demonstrating the different zones surrounding the missile track 
Here, immediately surrounding the missile track is the necrotic zone, whilst the edematous 
area surrounds the necrotic area where extensive neural damage is still seen (11). 
 
Within the haemorrhage, there were distinct necrotic zones of astrocytic and neuronal 
destruction. Furthermore, within the necrotic zones, polymorphonuclear (PMN) leukocytes 
acts as scavengers and appear within 1 day post-injury. Immediately surrounding the 
necrotic zone, is an edematous area with substantial numbers of macrophages. Loss of large 
amounts of brain tissue has been shown to cause edema formation which correlates with 
higher mortality, possibly because edema leads to secondary complications such as 
intracranial hypertension. Furthermore, within the oedematous zone, axonal fragmentation, 
clumping and varicose changes are seen. The degree of axonal damage correlates inversely 
with distance away from the track.  
1.3.10 OPC response to pTBI 
Oligodendrocytes are a glial cell type responsible for axonal myelination within the CNS, with 
one oligodendrocyte capable of myelinating around 40-50 axons (41). Myelination allows 
saltatory conduction throughout the CNS. In addition to myelination, oligodendrocytes 
provide trophic support to neuronal cells through lactate release.  
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OPC responses to traumatic injury within the CNS has been studied extensively. There is 
a consensus amongst researchers that neural glial antigen positive (NG2)+ cells 
proliferate and accumulate around and in the injury site (79). Previous studies employing 
stab wounds to the brain and contusion injuries to the spinal cord have led to a local 
increase in the number of NG2+ glia. Rabchevsky et al found an increased number and 
density of OPCs in the ventral-lateral funiculus of rats 2 days after contusion injury (80). 
McTigue et al reported a 3-5-fold OPC infiltration increase within lesioned tissue (81). 
Hampton et al found that in response to a cortical stab wound, OPCs infiltrate into the 
peri-lesional area from as little as 2 days post-lesion (82). In addition, it was noted that the 
OPCs appeared hypertrophic with many processes and increased NG2 immunoreactivity 
within 1.5mm of the lesion. Interestingly, in response to injury OPCs have also been 
reported to increase NG2 expression, withdraw finely branched processes and increase 
cell body size. The reaction of OPCs to cortical stab wounds has also been studied 
extensively. Buffo et al (2005) found a 3-fold increase in the density of OPCs surrounding 
a cortical stab at 7 day post-lesion, whereas Tatsumi et al (2008) reported 5-6-fold 
increase (83). As mentioned previously, the glial scar has 2 anatomical zones; the lesion 
core and the astrocytic zone surrounding the lesion core. In response to spinal cord injury, 
NG2+ cells have been known to populate lesion cavities, 2 days after injury (79). 
Furthermore, Hughes et al (2013) found in response to a laser lesion of the cortex, OPCs 
proliferate and migrate into the vacated space (84).  
Studies have shown that in response to generalised traumatic injury OPCs, which are 
normally in a quiescent state become activated (85). Post-brain injury mature 
oligodendrocytes are unable to produce new myelin sheaths and are often killed in the acute 
phase following injury (86). Renewal is thus dependent on the process of 
oligodendrogenesis. During injury, quiescent OPCs become activated and proliferate, and 
migrate towards the lesion and differentiate into mature oligodendrocytes (85). 
Oligodendrocytes are postmitotic cells, thus loss of these cells through injury is associated 
with a subsequent loss of myelination, which has been shown to contribute to cognitive 
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decline and can trigger depressive-like behaviour. Thus, formation of new oligodendrocytes 
post-injury is dependent on oligodendrocyte precursor cell (OPC) differentiation into 
oligodendrocytes.  
1.3.11 Regenerative therapies are needed for pTBI management  
The complex cellular responses to pTBI enables researchers to understand the 
pathophysiology and extent of pTBI injuries on a microscopic level, however these 
microscopic cellular responses translate clinically as significant cognitive and function 
impairment and debilitation, with severe cases resulting in death. Examples of current 
therapies being trialled include the potential of neural stem cell (NSC) transplantation into 
lesioned brain to facilitate functional recovery (87). However, although such therapies show 
promise, low cell viability post-transplantation means such therapies cannot maximise 
regeneration within the CNS. One potential solution to this is to transplant neural cell types in 
biomimetic biomaterials such as hydrogels into lesion sites to promote regeneration and 
reduce inflammatory processes (88–96). 
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1.4.1 Biomaterials such as hydrogels have been considered as a “pro-repair” 
strategy 
As discussed above, the CNS has an intrinsically lower regenerative capacity versus other 
tissues and thus researchers have been focusing on developing biomaterials which are “pro-
repair”. One such class of biomaterials which is widely tested within the CNS includes 
hydrogels. Hydrogels are a three-dimensional network of hydrophilic polymers comprised of 
up to 90% water and can be synthesized from natural or synthetic polymers (92). The tissue-
like, high-water content favours transplantation into soft tissues such as the CNS (97). 
Hydrogels can provide structural support to surrounding tissue and also serve as a trophic 
microenvironment via biomolecule and cell delivery. Specifically, tuneable hydrogel 
properties such as biomaterial stiffness (87,91,98,99) and thixotropic properties (90,99–105) 
makes hydrogels highly attractive biomaterials in regenerative research and clinical medicine 
(88–92,106). These specific properties are explored in turn in the following discussion.  
1.4.2 Gel stiffness can be controlled, and influences biological responses 
One major advantage hydrogels offer is the tuneable mechanical properties such as 
stiffness. Thus, for specific purposes one can tailor hydrogel stiffness to meet that need. For 
example, NSCs differentiate into three major cell types- neurons, astrocytes and 
oligodendrocytes. In general, NSCs and their subsequent differentiation is favoured in soft 
biomaterials with a relative stiffness of around 0.1-1 kPa (94,102,107,108). Extremes of 
stiffness including very soft biomaterials (<0.1 kPa) and very hard biomaterials (>100 kPa) 
have shown to be inhibitory to NSC viability, whilst glial differentiation is optimal in 
biomaterials with a stiffness of around 7-10 kPa. When cultured on hydrogel substrates, NSC 
preferentially differentiate into astrocytes on hard surfaces where as soft-intermediate 
stiffness (around 500 Pa) promotes NSC differentiation into neurons (94). Banjeree et al 
found a 17-fold increase in NSC number after 7 days in culture in alginate hydrogels of low 
stiffness, versus a 2-fold increase in the stiffest variant of their alginate hydrogel (94). 
Furthermore, at day 7, the highest levels of beta tubulin III (neuronal differentiation marker) 
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was observed in alginate hydrogels of low stiffness (183 Pa), and interestingly the modulus 
of brain tissues is also around 180 Pa. Thus, neural regeneration, proliferation and 
differentiation, can be induced by hydrogel scaffolds, depending upon their specific 
mechanical properties (109). 
1.4.3 Thixotropic and bio adhesive properties can be altered to facilitate minimally 
invasive applications 
The current trend in developing hydrogels for transplantation for regenerative therapies now 
emphasize “injectability” (90,100,103). Previously, hydrogels were implanted directly into the 
CNS/injury site, through a surgical procedure. Although effective, this process is not without 
limitations. Firstly, a surgical procedure is lengthier than an injection-based delivery system 
and will require multiple healthcare professionals to deliver this service. Secondly, surgery is 
invasive, which could be detrimental when considering hydrogels will usually be implanted 
into sites of injury and pathology. In addition, surgery also increases the risk of infection. 
Thus, injectable hydrogels provide a minimally invasive alternative to conventional surgery. 
In particular, this offers an attractive approach to fill cavities in pTBI. However, hydrogels are 
a jelly like, fibrous-cross linked polymer, composed of either natural substances- mimicking 
CNS extracellular matrix (ECM), or synthetic formulations (109,110). Thus understandably, to 
inject a hydrogel successfully, a hydrogel must possess thixotropic properties- the ability to 
withstand shear-thinning forces that hydrogels are subjected to as they the transit through a 
needle, and then subsequently gelate and “self-heal” at the target site without further 
intervention (100). Thus shear-thinning and thixotropic properties enable a pre-set 3D 
hydrogel construct tuned for a specific function ex-vivo, to then be delivered in vivo (99–101). 
Furthermore, injecting a pre-set shear-thinning hydrogel has inherent advantages over purely 
liquid hydrogel solutions which subsequently gelate;  the host environment may affect the 
hydrogel during crosslinking in non, pre-set hydrogels (99). Hydrogels with shear-thinning 
properties gelate much more rapidly at their target site (101). Finally, pure liquid 
uncrosslinked hydrogels may leak into surrounding tissue or perhaps dilute with local fluid 
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changing the physicochemical properties and concentrations of substances within the 
hydrogels (92).  
Furthermore, once a hydrogel is injected it is vital that the hydrogel remains in-situ at the 
target site and does not drift away. This is of importance when considering the role of 
hydrogels in forming “structural bridges” in pTBI management, thereby bridging the lesion 
made from the missile track and promoting regeneration. Thus, hydrogels for such purposes 
must intrinsically possess or can be engineered to have bio adhesive properties. For a 
hydrogel to be bio adhesive it must not drift away from the implanted site whilst also being 
cell adhesive. Oliviera et al reports that when injecting NSCs into the spinal cord 
intrathecally, the majority of cells sediment inferior to the cauda equina, and thus injecting 
NSCs within a bio adhesive biomaterial scaffold has been reported as novel solution (98, 
106). Strategies to improve bio adhesion include modifying the surface of the biomaterials 
with ECM proteins such as laminin, fibronectin and collagen (87,103,106,112,113). Such 
strategies have shown to improve tissue integration, viability of transplanted cells and axonal 
regeneration. For example, increased neurite outgrowth was seen in a poly(ethylene glycol) 
(PEG) hydrogel coated with fibronectin versus hydrogel without coating 
(87,103,106,112,113). 
1.4.4 Hydrogels offer pro-regenerative properties  
Hydrogels are biomaterial scaffolds and act as a protective three-dimensional (3D) matrix 
which also supports cellular growth (87,92,105,110,112,114). For example, dopaminergic 
neurons only have a 1-5% post transplantation cellular viability. Interestingly, 1x1013 
dopaminergic neurons need to be transplanted to yield a 1% post-transplantation survival 
(91,115). Adil et al (2017) transplanted neurons encapsulated in a hyaluronan-heparin matrix 
into rat striatum and demonstrated a 3.5-fold increased cell viability versus unencapsulated 
cells, and a 5.4 fold increase in TH+ neuronal survival versus injection of traditional 
unencapsulated cells (91). Furthermore, it was noted that there was 2-fold increase in neurite 
outgrowth within the hydrogel. Hydrogels are porous structures and thus allow bilateral 
cellular movement. Furthermore, hydrogels can recruit host cells to promote differentiation 
 
 
24 
 
and proliferation at the lesion site and thus can act as a transitory neuromimetic milieu (104). 
This is of paramount importance when considering the neuropathological consequence of 
pTBI. 
In addition, acellular biomaterial matrices have also been shown to possess regenerative 
properties. Hou et al found in a pTBI model that hyaluronic acid hydrogels modified with 
laminin disrupt glial scarring responses and promotes regeneration (116). Here, the hydrogel 
was implanted into a cavity for 6-12 weeks within the cortices of 8-week old Sprague-Dawley 
rat brains. The results showed that there was evidence of neurite regrowth, as myelinated 
axons could be seen infiltrating some of the implanted biomaterial, interestingly previous 
studies have also demonstrated that certain biomimetic biomaterials have promoted neurite 
outgrowth and angiogenesis into the implants (117,118). Furthermore, immunocytochemistry 
revealed that in control injured only cortices, an intense band of GFAP+ astrocytes along the 
length of the lesion could be observed whilst in hydrogel implanted cortices, there was little 
GFAP immunostaining along the perimeter of the implant (116).  
Furthermore, high magnification scanning electron microscopy revealed that blood vessels 
had grown into the 3D, porous hydrogel. Transmission electron microscopy (TEM) showed 
that there was evidence of cell migration into the implanted area; which was predominately 
glial cells, specifically morphologies consistent with astrocytes, microglia and macrophages 
could be identified (116). Here, astrocytes sent “pseudopod” like processes from the lesion 
margin into the implant, thus forming a structural bridge between lesion and implant (figure 
8a) (116).  
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Figure 8: Micrographs demonstrating glial cell infiltration into an implanted 
biomaterial (hyaluronic acid-laminin hydrogel) (116) 
Hyaluronic acid-laminin hydrogel implanted into the cortex of a lesion. A: Silver staining on a 
coronal section 6 weeks post implantation. The implantation region is on the right of dotted 
line, and normal tissues (asterisks) on the left. Numerous argyrophilic processes (arrows) are 
revealed within the biomaterial. B: The implantation region 12 weeks under TEM. Cells that 
migrated into the implanted area are mainly glial cells. Gels have already degraded and left 
much empty space (asterisks) between cells. An astrocyte sends pseudopod-like extensions 
(arrows) and contacts with others, forming cell bridges between the spaces. C: Macrophages 
(arrow) presented in the implanted area 12 weeks post-implantation could be discerned 
easily under TEM because they had ample short extension on their surface and plentiful 
vesicles in the cytoplasm. D: High power of a macrophage with vesicles due to endocytosis. 
Scale bars A: 20 μm. B-C: 3 μm. D: 20 μm.  
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High magnification TEM revealed that amoeboid microglia could be seen within the implant 
with numerous vesicles within the cytoplasm often containing degraded hydrogel (figure 8d). 
Thus, glial cell responses are critical to evaluate when studying the regenerative properties, 
a biomaterial possesses. Astrocytes are involved in biomaterial remodelling; specifically, 
astrocytic process extension and biomaterial infiltration bridges the lesion and provides 
structural support in turn allowing neurite outgrowth and angiogenesis within the implant. 
Secondly, microglia digest the biomaterial and influence the biodegradability profile. 
Currently, little is known about microglial dependent biomaterial degradation. Perhaps one 
could argue that highly immunogenic biomaterials lead to increased microglial infiltration and 
thus increased biodegradability rates which would thus limit the regenerative processes such 
as neurite outgrowth, astrocytic infiltration and angiogenesis into the implant.  
However, in vivo models including Hou et al have a major disadvantage when studying glial 
cell-biomaterial interactions. Hou et al found on post-mortem analysis of the tissue sections 
that after 12 weeks in vivo the hydrogel had “wholly degraded” and left an empty space in the 
reparative tissue. Thus, definitive cell-biomaterial responses cannot be determined at later 
time points. A solution to this is to study glial cell-biomaterial interactions through live 
imaging. Live in vivo imaging is extremely challenging and thus in vitro models are needed 
where live imaging can easily be employed. Current in vitro biomaterial testing predominately 
involves culturing neural cells in 3D matrices and comparing their response to two 
dimensional (2D) controls. For example, primary rat cortical astrocytes cultured in 3D 
collagen type 1 hydrogels, were deemed less reactive than those cultured on 2D surfaces. 
Specifically, astrocytes cultured within the hydrogel displayed decreased GFAP and CSPG 
immunofluorescence in addition to a significant reduction in GFAP mRNA and neurocan 
(119). However, such models do not simulate an injury environment and therefore cannot be 
considered pathomimetic to traumatic injury and thus there is no guarantee that neural cells 
will have similar biomaterial induced responses in the context of an injury. Currently, there 
are very few, if any, high throughput, in vitro multi-glial, pathomimetic, pTBI models capable 
of supporting biomaterial implantation. Furthermore, one can see from figure 8a that at 6 
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weeks in vivo, the biomaterial cannot be clearly identified, resulting in the researchers 
guessing the biomaterial’s location and determining cellular responses in the “implantation 
region”. In addition to live imaging techniques, researchers could counterstain or counter 
immunolabel the hydrogel, however currently there are very few, if any studies which have 
utilized such an approach.   
One key aspect which can limit CNS regeneration is immune and inflammatory responses to 
injury (15,18,24,68). This key response is also widely described in pTBI. Thus, it is vital for 
hydrogels to be biocompatible (95,97,103). Biocompatibility can be assessed by several key 
parameters.  Firstly, post-transplantation hydrogels should be minimally immunogenic and 
thus should not induce an adaptive nor innate immune response (40,103). Secondly, 
hydrogels should not be cytotoxic (97). Thirdly, hydrogels are manufactured to be 
biodegradable, whether this is a controlled degradation rate for “smart release” of its contents 
or time dependent inevitable hydrogel degradation (104). Thus, subsequent hydrogel 
degradation products should not be immunogenic/cytotoxic; whether this is due to exposing 
cryptic immunoreactive sites or degradation into to novel products with immunoreactive 
profiles (95,103,107,113,120–122).   
Thus, to improve hydrogel biocompatibility, two schools of thought typically exist with regards 
to hydrogel manufacturing. One classification includes synthetic hydrogels which are 
composed of specific chemical formulations with the intended purpose of being inert, 
minimally immunogenic and even anti-inflammatory/pro-repair (96,114). The second main 
classification includes “natural” hydrogels, which are created using the same components 
found within the host CNS ECM, thereby reducing the chance of rejection and recognition as 
a foreign object which could elicit an immune response (33,109,110).  
Collagen, a key component of the host CNS ECM has been widely used to manufacture 
hydrogels (92,107,123–125). Firstly, collagen is relatively cheap and widely available. 
Secondly, collagen hydrogels have shown to possess significant regenerative capability, 
potentiating cellular growth, differentiation as well as providing structural support.  
Furthermore, studies have demonstrated acellular collagen matrices promote both 
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angiogenesis and neurogenesis post-surgical brain injury (126). Furthermore, Chen et al 
(2019), demonstrated that a collagen-glycosaminoglycan matrix hydrogel implanted into 
surgical brain injury rat models was neuroprotective and anti-inflammatory (124). Specifically, 
implantation of the biomaterial significantly reduced the density of activated microglia as well 
as a significant decrease in the tissue concentration of the pro-inflammatory cytokines IL-6, 
TNF alpha. Interestingly, there was a significant increase in the anti-inflammatory cytokine IL-
10.  
1.4.5 Limitations in relation to hydrogel testing  
A major limitation of the Chen et al (2019) study and indeed most studies investigating 
hydrogel efficacy is that laboratory grade biomaterials are used, which are unapproved for 
human testing. Clinical grade biomaterials undergo an extensive and lengthy safety profiling 
process (up to seven years) by clinical safety governing bodies such as the food and drug 
administration (FDA), before approval for human use. Thus, even if research suggests 
hydrogel efficacy, there is no guarantee that such biomaterials will be suitable for clinical 
translation. Thus, increased testing with clinically approved neurosurgical grade biomaterials 
needs to be undertaken. One such biomaterial is DuraGen PlusTM, an ultrapure medically 
approved, type 1 bovine collagen-based hydrogel widely used in duraplasty. DuraGen 
PlusTM use in duraplasty allows fibroblast infiltration to allow for dural repair. Furthermore, 
bovine collagen use to fill the cavity in pTBI has also been described (127). Before exploring 
the potential of DuraGen PlusTM further, it is worth noting that bovine collagens in this case or 
indeed any animal derived biomaterials pose significant ethical and religious concerns. 
Specific religious groups and animal activists may object to the use of xeno-products and 
thus synthetic biomaterials can provide an ethically viable alternative. DuraGen PlusTM is 
reported to be minimally immunogenic, whilst also being compatible and mouldable for 
neurosurgical application. Early scientific studies indicate DuraGen PlusTM’s role as a 
neuroprotective and neuroregenerative matrix. Finch et al demonstrated DuraGen PlusTM use 
as a protective matrix for neural cell types as NSCs directly seeded onto the biomaterial had 
a cell viability over 94% (128). Finch et al also demonstrated that DuraGen PlusTM matrix 
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supports stem cells engineered with magnetofection technology and minicircle DNA vectors- 
a novel approach to cell engineering (129).  
Thus, DuraGen PlusTM matrices show promise for neural regeneration and its regenerative 
capabilities should be assessed in pTBI. Shin et al (2015) demonstrated that implantation of 
DuraGen PlusTM into an in vivo rat contusion TBI injury model significantly improved 
cognition, reduction in lesion volume and reduced neuronal loss within the hippocampus 
versus sham injury rats (130). Although this study shows promise for TBI, currently there are 
no studies which investigate DuraGen PlusTM’s efficacy in pTBI; the cellular responses of 
neural cells to this material have also not been documented in detail. To facilitate the 
development of such therapies, clinically predictive models of pTBI are required, within which 
potential therapies can be screened.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
1.5.1 An overview of in vivo pTBI models  
A variety of in vivo TBI models exist. These include the fluid-percussion model (115,125), the 
weight drop model (132), and the shock tube generated blast induced neurotrauma model 
(133). However currently, there are a limited number of in vivo pTBI models. Although not 
previously labelled as such in the literature, here the term large animal models will be used to 
describe those animals larger than rodents whilst small-animal models describe models of 
rodent size and smaller. Previously researchers focused on developing pTBI models in large 
animal models. Large animal pTBI models have introduced a ballistic injury in cats (134), 
dogs (135), monkeys (136) and sheeps (137). As discussed previously, pTBI results from 
any external insult which pierces the skull and enters the brain. Gunshot wounds and stab 
wounds to the brain represent common modes of trauma in both civilian and military 
populations. Thus, in vivo animal models have tried to replicate such trauma, through a 
variety of methodologies.  
1.5.2 An overview of in vivo pTBI models in large animals  
In the following discussion all animals used in the models were anesthetized. Zhou et al 
(1998) utilised the standard “Swedish missile trauma model” wherein 60 mongrel dogs were 
placed on a wounding frame and shot in the masseter muscle with a model 53 smooth bore 
rifle at a distance of 6 meters (135). The projectile was a 1.03-gram steel sphere shaped 
bullet. The aim of the study was to investigate cerebral injury associated with a maxillo-facial 
wound. The results showed cerebral hyperaemia, contusion, haemorrhage and haematoma. 
Microscopically, intracerebral micro-haematomas and necrosis of nervous cells was noted. 
Carey et al (1995), developed a pTBI model in mongrel cats where, the animals were placed 
on a stereotaxic frame. Researchers then removed the outer wall of the right frontal sinus 
allowing a missile to penetrate the intact posterior sinus wall (134). The bullet was a 2mm 31-
mg steel sphere and when fired penetrated the right frontal bone into the right cerebral 
hemisphere. This model showed vasogenic oedema around the missile track, raised 
intracranial pressure, raised blood glucose, and respiratory arrest. Finnie et al (1993) 
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developed a pTBI model which involved physically restraining a sheep and firing a bullet from 
a 0.22 calibre rifle at a distance of 3 meters in the temporal region of the sheep’s head (137). 
This resulted in tissue laceration, and stretch injuries to neurons, nerve fibres and blood 
vessels, as well as brain distortion. Thus, we can see that the glial responses to pTBI, have 
not been investigated in detail, rather macroscopic/clinically predictive features have been 
evaluated.  
Evaluation of large animal pTBI models 
Large animal pTBI models have inherent advantages over small animal models. Firstly, a 
larger brain to work with means introducing non-fatal injuries into brains is more facile. 
Secondly, due the larger brain size, these models provide closer mimicry to the human brain 
size. This also allows a similar injury which is encountered by a human for instance a bullet 
to be accurately replicated, since most bullets are larger than rodent brains thus the specific 
injury would not be accurately simulated in rodent brains. 
The main disadvantage of such large animal models is that they are inherently low 
throughput and obtaining the resources to house and maintain these animals is expensive. 
Secondly, there are major ethical implication associated with large animal models over small 
animal models, as some would argue that larger animals are more sentient animals than 
rodents. In addition to this, these models are highly invasive/traumatic and raise major ethical 
concerns. Thirdly, the majority of these models focus on macroscopic pathological and 
physiological consequences of pTBI and not the cell-specific responses such as the glial 
response- which have key roles in pTBI.  
1.5.3 An overview of in vivo rodent pTBI models   
As discussed above large animal pTBI models have several limitations. Thus, researchers 
have focussed on more accessible and facile small animal in vivo models to facilitate 
research into pTBI pathophysiology.  
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Cernak et al (2014) developed an non-fatal in-vivo mouse pTBI model whereby a modified air 
rifle delivers a pellet which subsequently hits a small probe; the small probe then enters the 
brain (figure 9) (39).   
 
Figure 9: Overview of a penetrating device setup 
A: Overview of a penetrating device setup. White arrow- penetration rig mouthpiece, Black 
arrowhead – stereotactic manipulators. Black arrow – Probe holder, white asterisk- air-rifle 
barrel. B/C: Images of the probe holder before (B) and after (C) impact of pellet.  
 
The same model by Cernak and colleagues has previously been used in rats (67). Cernak et 
al found increased tissue destruction and neuronal degeneration in lesioned brains. 
Furthermore, reactive gliosis was also noted and was quantified by measuring staining 
intensity of GFAP (section 4.1) for astrocytes and Iba1 for microglia. Specifically, there were 
significantly increased GFAP immunoreactive astrocytes at 72 hours post-injury with 
persistence up to 7 days post-injury. Cortical microglial activation was seen up to 7 days post 
injury (39).  
On the other hand, Williams et al (2007) developed an in vivo pTBI model simulating the 
damage resulting from a penetrating bullet round by inserting an inflatable penetrating probe 
into the right frontal hemisphere of Sprague -Dawley rats (68). The Williams et al model 
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resulted in significantly increased GFAP immunoreactive astrocytes emerging 6 hours post-
injury which peaked at 72 hours post-injury and peak microglial activation at 72 hours post- 
injury with resolution by day 7(68). Williams et al results are different to Cernak et al. Cernak 
et al suggests the difference may be explained by the methods of injury, namely a projectile 
induced trauma in Cernak et al model versus inflatable balloon in the Williams et al model. 
Interestingly, both studies did not count microglial numbers per unit area - another commonly 
used analysis to demonstrate microglial response to injury. Specifically, Robel et al 2011 
found significantly increased microglial numbers surrounding stab wound injury site versus 
control in a pTBI stab wound model (71). 
Bardehle et al 2013 studied, astrocytic responses to pTBI by localized stabbing of the 
somatosensory cortex in mice brain. Astrocytes became hypertrophic and had increased 
GFAP expression whilst also subsets of astrocytes polarized towards the lesion by extending 
long polarized processes towards the lesion (70). Interestingly, astrocytes post-injury extend 
processes towards the lesion and have been named as “palisading” or “polarized astrocytes” 
(138) . Astrocytic polarization towards the lesion has been considered a hallmark of the glial 
scar. Live in vivo imaging demonstrated that astrocytes near the vicinity of the injury orientate 
themselves towards the lesion and extend long processes (figure 10).  
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Figure 10: Palisading astrocytes respond to the lesion 
 In vivo astrocytes respond to pTBI by hypertrophic changes and a hallmark palisading 
astrocytic layer of cells closest to the lesion with decreasing process extension as distance 
from lesion increases. 
 
Astrocytes posterior to the palisading layer, are also hypertrophic and orientate processes 
towards the lesion. As the distance from the lesion increases, the hypertrophic responses 
tend to decrease. Microglial responses to injury are rapid, often within minutes, whilst 
hypertrophic astrocytes and GFAP upregulation occurs 2-3 days post-injury with palisading 
astrocytes observed 1-week post-injury. Interestingly palisading astrocytes adjacent to the 
lesion vicinity retain their hypertrophic morphology permanently whilst hypertrophic 
astrocytes further away from the lesion site return to normal.   
Zhao et al (2019) developed a rat pTBI model by creating a craniotomy in the left parietal 
bone and placing an impact tip on the dura inside the bone window (66). Subsequently, a 
40g weight impactor was dropped from a height of 20 cm onto the impact tip. The lesion was 
then sutured and closed. The sham group received only a craniotomy without the injury. The 
results showed the increased presence of Iba1 positive reactive amoeboid microglia in 
ipsilateral lesioned rat brains 24 hours post-injury versus sham- where most microglia 
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adopted a ramified and processed morphology. Similarly, ramified astrocytes with fine 
filopodial processes and small cell bodies were seen in sham operated tissue, whilst 
hypertrophic reactive astrocytes with large cell bodies and extended processes were seen 
around sites of lesion. Analysis with ImageJ software demonstrated that microglia and 
astrocytes in lesioned tissue had significantly increased expression of Iba1 and GFAP 
immunoreactivity respectively. Interestingly, it was also noted that glial reactions occurred in 
remote parts of the uninjured tissue as well as lesioned tissue. Microparticles- a kind of 
extracellular vesicle are released from glial cells and dying cells and have been postulated as 
a potential reason as to why glial reactions are seen in remote uninjured regions of the brain. 
Extraction and addition of microglial-derived microparticles have shown to propagate 
neuroinflammation and activate resident microglia, highlighting that glial cell responses can 
be widespread (66). 
Evaluation of rodent pTBI models 
Rodents are significantly cheaper and more accessible than larger animals to most 
laboratories. Specifically, mice offer several advantages over rats: the ability to use knockout 
and transgenic mice and the significantly lower costs associated with housing, maintaining 
and purchasing mice versus rats. In addition, rodent brains mimic the neuroanatomical 
proportions seen within human brains. Finally, the majority of existing rodent pTBI models 
allow researchers to focus on cellular responses to pTBI, in particular the glial cell 
responses. 
However even small animal pTBI models are low throughput versus in vitro cell culture-
based systems. Secondly, the models are technically challenging and require significant 
training and are subject to Home Office regulations and obtaining the relevant licenses. 
Thirdly, injury methods are very invasive and pose significant ethical considerations. Finally, 
specialist equipment is required to reproducibly introduce injuries (figure 9) adding to the 
expense and accessibility only some laboratories may have.  
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1.5.4 The use of organotypic brain slice cultures as in vitro pTBI models 
Organotypic brain slices are thin slices of brain tissue which are maintained in culture for 
extended periods typically greater than 7 days (139–141). Currently, very few studies have 
used organotypic slice cultures as models for pTBI. Krings et al (2016) subjected organotypic 
hippocampal slice cultures to trauma through dropping a metal stylus under 
stereomicroscopic control from a height of 7mm (142). This is a well-established method for 
reliably introducing lesions into organotypic slice cultures. In this study the efficacy of 
desflurane in neuroprotection post-pTBI was evaluated through trauma intensity measures 
(trauma intensity was assessed by measuring propodium iodide uptake by damaged cells). 
No pathological pTBI features such as the glial scar were assessed in this study. Weightman 
et al (2014) developed an in vitro spinal cord slice model where injury was reliably introduced 
with a scalpel. Post-lesion astrocytes became hypertrophic and intensely expressed GFAP 
significantly higher in the first 100 microns of the lesion. Furthermore, microglia infiltrated the 
lesion, with numbers peaking at day 5 post-injury. It was also noted that the microglia in the 
lesions had amoeboid morphologies versus  ramified microglia seen in control samples 
(143). 
Evaluation of organotypic brain slice pTBI models 
Generally, brain slices are able to maintain neuronal function and synaptic circuity whilst also 
preserving brain architecture (141). Also, unlike in vivo systems, brain slices allow good 
experimental access and control. Furthermore, brain slices can recover from the trauma of 
excision before further experiments (139). Finally, brain slices allow for the study of 
interaction of many cell types including neurons, astrocytes, OPCs and microglia.   
However, there are considerable limitations with organotypic brain slice models. Firstly, brain 
slice models are still moderate throughput and although brain slice preparation is relatively 
facile, the current penetrating lesioning methodologies are challenging versus cell culture 
based in vitro models which often involve scratching confluent cultures with sterile pipette 
tips/needles (70,71,139,144,145). Secondly, such models have a finite length of viability as 
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they are maintained in vitro. Thirdly, to prepare brain slices the intact brain is sectioned and 
thus this process of sectioning may contribute to cellular activation seen in response to 
injury, in addition to the presence of increased numbers of dead cells. Finally, organotypic 
brain slices still require the use of animals and thus only contribute the Reduction and 
Refinement of animal models and not the Replacement of animal models.  
1.5.5 In vitro models could provide many solutions to the limitations posed by current 
in vivo pTBI models  
In vitro pTBI models offer many advantages over in vivo systems. Firstly, the majority are 
facile, high throughput, easily reproducible and allow monitoring of single cell responses 
using standard and widely available microscopy methods.  
The most basic in vitro models utilize immortalized cell lines. Immortalized cell lines are 
widely used as they are easy to procure, widely available, well characterized, inexpensive 
and relatively robust. However immortalized cell lines have been known to suffer from 
disruption of contact dependency and poor adhesion (140). Furthermore, many cells are 
resistant to cell death, prone to cryptic contamination and have an increased risk of cellular 
aneuploidy (146).  
Disassociated primary cultures offer another system to study pTBI features. Most models 
utilize a monoculture format. Etienne-Manneville et al (2006) demonstrated that a confluent 
astrocytic (mono) culture on a glass coverslip can be scratched with a 2 μl micropipette tip to 
produce a 300 μm lesion. Post-lesioning, hallmark astrocytic polarization and process 
extension towards the lesion site “analogous to palisading astroglia in traumatic brain injury” 
was seen (147). Furthermore, Nishio et al (2005) showed that when a confluent astrocyte 
monoculture is scratched, cells at the lesion edge increased expression of intermediate 
filaments such as GFAP. In addition to this, astrocytes at the edge of the lesion became 
polarized with unidirectional processes and migrated to fill the lesion area (148). This shows 
that in vivo reactive astrogliosis seen in response to pTBI in vivo can be reliably replicated in 
vitro.   
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The major disadvantages of using monocultures however is that they are overly simplistic 
and do not replicate the complexity of multiple cell types which are present within the CNS. 
Liddlelow et al (2017) showed that classically activated neuroinflammatory microglial release 
of IL-1 alpha , tumor necrosis factor (TNF) and C1q in response to neuroinflammation can 
induce A1 reactive astrocytes both in vivo and in vitro (64). Specifically, absence of a 
microglial and OPC component means such models lack inter-glial communication such as 
microglial dependent-astrocytic activation, a key initiation step for glial scar formation. Thus 
ideally, a good model should contain all of the neural cell types. 
Finally, co-cultures, allow the presence of multiple glial cell types. This enables intercellular 
cross talk and provides a more complex model than overly simplistic monocultures.  
Commonly used co-cultures include astrocyte-neuron and astrocyte-microglia models (149). 
However, currently there seems to be very little literature describing an injury model 
application of these co-cultures. Perhaps this is due to the difficulty and time required to 
create stoichiometrically defined neural co-cultures in the first instance. 
More recently, researchers have developed and refined brain-on-a-chip models to simulate 
TBI. These models are 3D cell-cultures which attempt to model the physiological responses 
of the brain in a microfluidic environment (140). Currently, these models allow pathology to 
be created on a chip and a large number of chemicals can be screened to evaluate positive 
physiological effectiveness. TBI has previously been modelled by applying pneumatic 
pressure through a deformable plate upon which the cultures had been placed, leading to a 
strain injury (140). Here, axonal injury and biochemical changes along with mitochondrial 
membrane potentials were studied (140). Although such models have inherent advantages 
over in vivo alternatives including being higher-throughput and providing a more ethically 
viable alternative, these models tend to be very expensive to establish(140). In addition, the 
ability to replicate pTBI on a chip is currently limited. Also, brain-on-a-chip models only 
contribute the Reduction and Refinement of animal models and not the Replacement of 
animal models and thus more ethically viable alternatives need to be considered.  
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1.5.6 Reduction, Replacement and Refinement of animal models 
There are several disadvantages of cell-culture based models: cells can behave differently, 
in vivo versus in vitro and the dissection process used to harvest cells is intrinsically injurious 
in nature. However, cell culture based in vitro models are facile and high throughput, with the 
possibility of large numbers of technical replicates to be easily and simultaneously obtained 
for experimental reproducibility. Currently, there are very few if any in vitro cell-culture based 
multi-glial pTBI models which are capable of biomaterial testing, and thus it is vital for 
researchers to develop these models in the future.  
Despite the inherent limitations of in vivo models, in vitro alternatives cannot outright replace 
such models, as rigorous animal testing will always be required prior to human trials. 
However, in line with the Reduction, Replacement and Refinement (3R’s) of animal models 
initiative, such in vitro models can reduce unnecessary animal experimentation in the early 
stages of research and development, and provide researchers with detailed solutions prior to 
vigorous animal testing (figure 11) (150).  
 
Figure 11: A schematic displaying the principles of the Replacement, Reduction and 
Refinement (3R’s) of animal models initiative (150) 
 
Furthermore, such models allow key regenerative biomaterials/strategies to be identified, 
which can then be trialled in more complex animal models (150). 
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1.5.7 Current models used to test biomaterials in pTBI 
Current methods predominately focus on in vivo biomaterial testing. For example, electro 
spun nanofiber scaffolds were implanted into the lesioned brains of male Wistar rats (151) 
(53). The results showed there was no significant inflammation from either microglia or 
astrocytes, furthermore the scaffold supported neurite infiltration. Similarly, Xiong et al 
implanted a type 1 collagen scaffold embedded with human marrow stromal cells into an in 
vivo TBI model and found a significantly increased cell viability versus cells transplanted into 
culture medium alone (151,152).  Although, biomaterial testing in vivo is plentiful the same 
advantages and disadvantages of these models apply as discussed previously (section 
1.5.6). Thus in vitro models could offer invaluable insight and accessibility into studying the 
regenerative capability of biomaterials. Weightman et al described an in vitro biomaterial 
testing application for spinal cord injury and is one of the only described injury in vitro 
biomaterial testbeds (143). The model consists of organotypic spinal cord slices cultured in 
vivo, which can be reliably injured with a scalpel, the efficacy of nanofibers was then tested 
by placing the nanofiber meshes over the lesions and alignment of astrocytes neurites was 
determined.  The results showed that in injury states, astrocytes became hypertrophic whilst 
also expressing GFAP in the first 100 microns adjacent to the lesion versus tissue further 
away. These pathological hallmarks are analogous to the glial scar. Interestingly, poly-D-
lysine coated laminin nanofiber implantation resulted in increased alignment of astrocytes 
and polarization of long thin processes towards the material. On the other hand, uncoated 
nanofibers behaved similarly to control samples without nanofibers as “no evidence of 
astrocyte attachment and alignment was observed”. Although, this model allows for key 
astrocytic-biomaterial interactions, there is one key disadvantage. Firstly, the fact that the 
control samples did not exhibit astrocytic polarization and a palisading astrocytic layer was 
not formed, highlights that the astrocytes in this model react morphologically differently to 
other pTBI models where the palisading astrocytic morphology in response to injury has 
been extensively characterized. Astrocytic process extension and entangulation has been 
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associated as a key step in forming a glial scar barrier. Furthermore, extensive microglial 
attachment to the nanofibers was noted.  
Although, the Weightman et al model is a progressive step towards in vitro biomaterial 
testing applications in neurological injury, organotypic slice cultures have inherent 
disadvantages (section 1.5.4). Thus, currently there is a critical need for cell culture based in-
vitro TBI model which can support biomaterial testing. Such a model if possible, should be 
novel, high-throughput, facile, contain the major the glial cell types and once injured should 
be neuropathomimetic to pTBI. 
Thus, in order to facilitate the development of such a model, the following objectives have 
been devised: 
1.5.8 Objectives 
1. Develop an in vitro injury pTBI model, capable of supporting biomaterial 
implantation to assess regenerative strategies. 
2. Characterize the glial responses to injury and determine whether such a model 
can simulate in vivo pTBI glial responses. 
More detailed and specific objectives are listed under the corresponding experimental 
chapters. 
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Chapter 2 
Materials and Methods 
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2.1 Materials  
Primary cell cultures: All culture grade plastics were from Thermo Fisher Scientific 
(Loughborough, UK). Media components included Dulbecco’s Modified Eagle Medium, 
Neurobasal-A Medium, Foetal bovine serum (FBS), penicillin-streptomycin solution, B27 
supplement, sodium pyruvate and glutaMAX-I. Media, including media supplements and 
reagents except where stated were from Thermo Fisher Scientific (Loughborough, UK), and 
Sigma-Aldrich (Dorset, UK). 
Biomaterial implantation experiments: Neurosurgical biomaterial DuraGen PlusTM was from 
Integra LifeSciences (New Jersey, USA). The Mcllwain tissue chopper was from The Mickle 
laboratory engineering co. Ltd (Guilford, UK). Paraformaldehyde (PFA) was from Thermo 
Fisher Scientific (Loughborough, UK). 
Antibodies for immunocytochemistry (ICC): Primary antibodies were anti-glial fibrillary acidic 
protein (GFAP), from DakoCytomation (Ely, UK), anti-Iba1and biotin-conjugated lectin from 
Thermo Fisher Scientific, anti-NG2 from Milipore (Massachusetts, USA), purified anti-neuron-
specific class III beta-tubulin (Tuj1) from Biolegend (California, USA), anti-A2B5 from Sigma-
Aldrich (Dorset, UK). 
Secondary antibodies were, Fluorescein isothiocyanate (FITC)-conjugated donkey anti-
mouse, -rabbit, -goat and cyanine 3 (Cy3) donkey anti-mouse, and -goat, which were all from 
Stratech Scientific (Suffolk, UK). FITC-conjugated anti-biotin secondary antibody was also 
from Stratech Scientific (Suffolk, UK). Vectashield mounting medium containing 4′,6-
diamidino-2-phenylindole (DAPI) was from Vector laboratories Inc (Peterborough, UK). 
Normal donkey serum (NDS) was from Stratech Scientific (Suffolk, UK) and Triton X-100 was 
from Sigma-Aldrich (Dorset, UK). 
Cells and biomaterial histological staining experiments: Haematoxylin and Eosin (H&E) 
staining kit was from Sigma-Aldrich (Dorset, UK). 3,3'-diaminobenzidine (DAB) Substrate Kit, 
Peroxidase (HRP), with Nickel (SK-4100) was from Vector Laboratories. Picrosirius red 
solution was from Sigma-Aldrich (Dorset, UK).  
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2.2 General Protocols 
2.2.1 Coverslip preparation 
Coverslips were washed with ethanol 70% and added to 24 well plates where they were 
coated with poly-D-lysine for 20 minutes and washed with distilled water (2x washed, 5 
minutes/wash). 
2.2.2 Cell fixation  
4% PFA in phosphate buffered saline (PBS) solution was prepared prior to fixation and 
added to the 24 well plates. The cells were fixed at room temperature for 20 minutes, then 
washed three times with PBS. For micro-mixed glial (Model 1- mixed-glial cultures seeded 
into a micro-well format) experiments, the cells were fixed at days 14,15 and 21 in vitro, (see 
3.3.2, for further details). For neuron-glia (model 2) experiments, the cells were fixed at day 
14in vitro (see 3.39, for further details). 
2.2.3 Immunocytochemistry 
Post-fixation cells were incubated with normal donkey serum in PBS with 0.3% Triton X-100 
for 30 minutes before the primary antibodies Tuj1 1:250, GFAP 1:500, Iba1 1:500, Lectin 
1:500 and NG2 1:500 were incubated with the cells overnight at 4°C (table 2).  
Cell type immunolabelled Primary antibodies and 
labelling molecules (species 
of origin) 
Secondary antibodies 
Neurons TUJ1(mouse)        CY3 Donkey anti-mouse 
Astrocytes GFAP (rabbit) FITC Donkey anti-rabbit 
Microglia Iba1 (goat) CY3 Donkey anti-goat 
Lectin (Lycopersicon 
esculentum) 
FITC-conjugated anti-biotin 
OPCs A2B5 (mouse) CY3 Donkey anti-mouse 
NG2 (rabbit) FITC Donkey anti-rabbit 
 
Table 2: Antibodies used to detect various neural cell types 
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The following day primary antibodies were removed, and samples were washed thrice with 
PBS, and incubated with NDS for a further 30 minutes at room temperature. FITC 1:200 and 
Cy3 1:200 secondary antibodies diluted in NDS were added to the wells and incubated for 2 
hours. The cells were then washed three times with PBS.  
2.2.4 Coverslip mounting 
Coverslips in 24 well plates were carefully lifted up with a 21g needle and carried with fine 
forceps onto a drop of DAPI mounting medium on a glass slide. The coverslips were then 
sealed with nail varnish along the edges.  
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2.3 Preparation of mixed-glial cultures 
The mixed-glial cultures have traditionally been established as bulk cultures. Here 
disassociated cerebral cortices are seeded into T175/T75 culture flasks. In this thesis, the 
term “macro-mixed glial culture” will be used to refer to the traditional bulk mixed-glial culture 
format, whilst the term “micro-mixed glial culture” will be used to refer to the mixed-glial 
culture seeded into a 24 well micro-well format. The term “neuron-glia” model is used to 
describe an adaptation of the micro-mixed glial model established with neuronal medium 
versus D10 medium. Animal care and use was according to the Animal (Scientific 
Procedures) Act of 1986 (UK) with approval by the local ethics committee.  
2.3.1 Preparation of macro-mixed glial cultures (bulk cultures)  
Primary mixed glial cultures were prepared according to the Mccarthy and de Vellis protocol 
(153). For this, eight to twelve CD1 mouse pups per litter at postnatal day 1-3 (P1-P3), were 
anaesthetized using pentobarbitone via intraperitoneal injection. The mouse pups were then 
decapitated, and each brain was then dissected out of the skull and placed in PBS on ice. 
Under a laminar hood the brains were transferred to a fresh petri dish containing PBS and 
onto a sterile hand towel. The olfactory bulbs, cerebellum, medulla and midbrain were 
removed from the brain using curved forceps, leaving the only the cerebral cortex. The 
cerebral cortex was subsequently rolled along the hand towel to remove the meninges. The 
cortices were then transferred into 35mm petri dishes and mechanically dissociated with a 
sterile scalpel. 2ml of PBS was added to the dissociated cortices, the suspension was then 
transferred into a universal tube where the tissue was triturated 40 times with a plastic 
Pasteur. The suspension was further triturated thrice each by using syringes attached to a 
21g and 23g hypodermic needle and placed through a 70-micron and 40-micron strainer. 
The filtrate was then centrifuged at 1000 rpm for 4 minutes. The supernatant was removed, 
and the pellet was loosened by agitating the universal tube and diluted in1ml of the cells 
suspension was diluted with Dulbecco’s Modified Eagle Medium containing an additional 
10% foetal bovine serum, 2 mM, glutaMAX-I, 1 mM sodium pyruvate, 50 μg/ml streptomycin 
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and penicillin (D10). A cell count was performed by mixing 10 μl cells with 40 μl of 0.4% 
trypan blue and adding this to a Neubauer chamber. The cells suspension was then seeded 
on to pre-prepared poly-D-lysine coated T175 flasks, at a fixed concentration of 0.83 x105 
cells/ml. After seeding, cultures were left in an incubator 37°C in 5% CO2 95% humidified air.  
The cultures were only removed from the incubator for medium replacement; at 1 day post-
seeding 100% of the medium was changed (300 μl of D10), then every 2/3 days, 50% 
medium changes with D10 (150 μl of D10). Prior to medium replacement the cultures were 
imaged under a light microscope (section 2.3.1) within the same culture room to track culture 
development and confluency. The macro-mixed glial cultures (mixed-glial cultures 
established as bulk cultures in T175 culture flasks) were conducted in parallel to the micro-
mixed glial cultures to determine whether there were any noticeable differences in terms of 
culture development and confluency versus the micro-mixed glial cultures (see 3.3.2 for 
details).  
2.3.2 Preparation of micro-mixed glial cultures 
The mixed-glial cultures were prepared according to the protocol in section 2.3.1, except the 
cells suspension was seeded on to pre-prepared poly-D-lysine coated coverslips in a 24 well 
plate at a fixed concentration of 0.83 x105 cells/ml in addition to T175 culture flasks. After 
seeding, cultures were left in an incubator (37oC, 5% CO2, 95% humidified air). The cultures 
were only removed from the incubator for medium replacement; at 1 day post-seeding 100% 
of the medium was changed (300 μl of D10), then every 2/3 days, 50% medium was 
changed with D10 (150 μl of D10). Prior to medium replacement the cultures were imaged  
under a light microscope (section 2.3.1) within the same culture room to track culture 
progress. Here, both bulk (macro) mixed-glial cultures and micro-mixed glial cultures were 
imaged in parallel, to document culture development, including the confluency of astrocytic-
like morphologies forming an astrocytic bed layer and the presence of microglial/OPC- like 
morphologies developing on top. The bulk cultures were established in parallel to determine 
whether, seeding the mixed-glial suspension in a micro-well format altered the development 
and confluency of the cultures.  At day 14, when the cultures became confluent, they were 
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fixed in PFA (section 2.22), and single immunocytochemistry was performed (section 2.2.3) 
to label astrocytes with GFAP, microglia with Iba1/lectin and OPCs with NG2/A2B5 (figure 
12). 
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                     Figure 12: A schematic showing the protocol undertaken to establish the micro-mixed glial model (Model 1)
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2.3.3 Establishment of an injury paradigm in Model 1: 
By day 14, Model 1 was confluent and 24 well plates which contained the cultures were 
placed in the laminar flow hood. A sterile P200 pipette tip was scraped across the coverslip 
from one corner of the coverslip to the other to create a transection injury. Note, it is crucial 
that one applies the tip perpendicularly to the glass coverslip and not angled to ensure the 
full diameter of the pipette tip is in contact with the culture, enabling the creation of a lesion 
with lesion edges at a consistent distance apart and removal of adhered cells along the 
whole lesion. Post-lesioning, the D10 medium was discarded to remove cellular debris and 
fresh medium re-added to the wells. The remaining cultures were re-incubated (37oC, 5% 
CO2, 95% humidified air).  
To identify the lesion margins including measurement of the lesion width (section 2.4.2), the 
cultures were fixed in PFA immediately post-lesioning and ICC performed to label the 
astrocytes with GFAP and DAPI (figure 13).  
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                              Figure 13: A schematic showing the steps taken in order to establish a lesion in Model 1
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2.3.4 DuraGen PlusTM preparation  
DuraGen PlusTM was supplied in sterile packaging as a 10 x 12.5 x 2 cm dry, square, piece of 
material. Using a sterile scalpel, under a laminar hood, a 5 x 5 x 20 mm piece was isolated. 
This was placed in a petri-dish and 3 drops of PBS from a plastic Pasteur was added onto 
the biomaterial. The DuraGen PlusTM absorbed the PBS. This helped to adhere the 
biomaterial with the petri-dish enabling the biomaterial to remain in-situ whilst chopping. The 
Mcllwain tissue chopper was then set to chop the DuraGen PlusTM at a thickness of 250 
microns, here parallel cuts were made slicing the biomaterial at the pre-set thickness. The 
DuraGen PlusTM was then placed onto a petri dish which had a pre-measured grid with sub-
mm dimensions and ca 800 x 1200 x 250 µm pieces were then prepared using a sterile 
scalpel.  
2.3.5 Establishing a protocol for implanting a DuraGen PlusTM sheet into the lesion  
The penetrating lesion was made in cultures in accordance to section 3.3.3. The cultures 
were then re-incubated for 2 hours. After 2 hours, the cultures were brought into a laminar 
flow hood which contained a dissection microscope. The medium was then removed 
completely and a pre-prepared DuraGen PlusTM sheet (section 2.2.6) was inserted using 
fine forceps under microscopic guidance at 12.5x magnification, into the lesion. Note it is 
vital to add the biomaterial in the absence of medium, since this promotes biomaterial 
adherence to the glass coverslips. Attempts to implant the biomaterial in media results in 
the biomaterial floating. Once the DuraGen PlusTM was implanted into the lesion, 200 μl of 
fresh D10 is then slowly added to the wells. The cultures were then incubated (37oC, 5% 
CO2, 95% humidified air), with 50% medium changes every 2 days. The cultures were 
fixed at 1 day and 7 days post-lesion. ICC was performed to label astrocytes (GFAP), 
microglia (Iba1), and OPCs (NG2). There were 3 experimental groups (i) lesioned (ii) 
unlesioned (iii) DuraGen PlusTM treated lesions. All three groups underwent the same 
subsequent protocol steps (figure 14).  
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                        Figure 14: A schematic showing the steps taken in order to implant a biomaterial into the lesion 
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2.3.6 Pilot study to develop a model (Model 2) containing neurons and the major glial 
cell types  
Model 1 lacks a neuronal component and thus an effort was made to develop a model which 
contained all of the neural cell types. Here, the same protocol was followed in section 3.3.2 
to establish a micro-mixed glial culture with two main differences: (i) Model 2 was established 
and fed with neuronal medium (96% Neurobasal A, 2 mM Glutamax-I, 2% B27 and 
penicillin/streptomycin), (ii) the cells were seeded at a higher density of 4 x 105 cells/ml. After 
seeding, the cultures were fed every 2/3 days with neuronal medium (50% change). The 
cultures were only removed from the incubator for feeding and for observation of the culture 
including development, confluency, and assessment of the cell morphologies. By day 14 
these cultures were deemed confluent and fixed in 4% PFA (section 2.2.2). ICC was 
performed in accordance to the protocols set out in section 2.2.3, to label neurons (Tuj1), 
astrocytes (GFAP), microglia (Iba1) and OPCs (NG2). The glass coverslips containing the 
samples were mounted onto glass slides (section 2.2.4) and imaged under a fluorescence 
microscope (section 2.3.1). 3 random separate fields (imaged initially on the DAPI field in 
three separate regions) of x400 magnification images were taken for each stain were taken. 
Since this was a pilot study, the images were used to determine whether Model 2 contains all 
of the neural cells and a visual assessment without quantitative or statistical methods was 
performed to determine a rough estimation of the proportions of each cell type within the 
model (figure 15). 
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                                Figure 15: A schematic showing the protocol undertaken to establish the neuronal- glia model (Model 2) 
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2.4 Imaging  
2.4.1 Light microscopy  
A Motic AE31E phase contrast microscope, with Moticam 3Plus camera and software 
was used for phase image characterization of the macro-mixed glial cultures (bulk cultures) 
and micro-mixed glial cultures. Light microscopy was also used for cell and biomaterial 
histological staining experiments to visualize the lesion at 0 hours post-lesion and after 
biomaterial addition at 2 hours post-lesioning. Fluorescence microscopy was used for all 
other experiments unless otherwise stated.  
2.4.2 Polarizing light microscopy  
A Nikon Eclipse LV100N fitted with a digital camera was used to visualize the birefringence 
of collagen fibres in DuraGen PlusTM (See 3.3.6 for experimental details).   
2.4.3 Fluorescence microscopy  
Fluorescence microscopy was used to characterize both the micro-mixed glial model and 
neuronal-glia model at day 14, after immunostaining. Fluorescence microscopy was also 
used to assess cellular responses to lesions and biomaterials at 0 hours post-lesion, 1 day 
post-lesion and 7 days post-lesion. The analysis of each experimental condition was 
conducted using fluorescence images captured at low magnification on an AxioScope A1 
microscope fitted with an Axiocam ICc1 digital camera, utilising Axiovision imaging software 
by Carl Zeiss Microimaging, Gmbh (Germany).  
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2.5 Analyses  
2.5.1 Characterizing the glial cell proportions in the micro-mixed glial model at day 14  
P1-P3 mice derived micro-mixed glial cultures at day 14 in vitro were fixed in 4% PFA and 
stained for GFAP, Iba1, NG2 and DAPI. Fluorescence micrographs were taken and merged 
using Axiocam software and all analyses were performed using ImageJ software (NIH USA). 
Culture characterization for GFAP+, Iba1+, NG2+ cultures at day 14 was quantified from 
fluorescent images taken from three random fields (3 separate regions of the coverslip using 
DAPI only channels first) per coverslip with at least 100 nuclei assessed from each 
experiment. Each nucleus was counted as positive or negative for GFAP, Iba1 or NG2, and 
thus a total proportion of positive cells was determined.  
2.5.2 Evaluation of the lesion width at 0 hours post-lesion 
P1-P3 mice derived micro-mixed glial cultures, lesioned after 15 days in vitro were fixed in 
4% PFA immediately after lesioning (section 3.3.3). To assess the reproducibility of the 
lesioning technique (section 3.3.3), the diameter of the lesion was assessed across four 
litters (1 lesion per litter). Here, fluorescence micrographs of GFAP stained lesions at 0 hours 
post-lesion were taken by obtaining low magnification x100 (x10 objective) images of the 
lesion. The total length of the visible lesion (where both corresponding edges of the lesion 
edge could be visualized) was measured and divided by ten, providing ten points at which 
measurements were taken from one lesion edge to the other (perpendicular to the direction 
of the lesion, with all measures being parallel to each other). 10 measurements per lesion 
per culture were averaged to create a graph displaying the average lesion width per culture, 
(n=4). Quantification was carried out using ImageJ analysis software (NIH USA).   
2.5.3 GFAP optical density fold-change measurements  
P1-P3 mice derived micro-mixed glial cultures, lesioned after 15 days in vitro were fixed in 
4% PFA at 1 and 7 days post-lesion and stained for GFAP and DAPI. Low magnification 
x100 GFAP images of the lesion edge were obtained and converted to grayscale. A 
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superimposed rectangle (aligned with lesion edge) of sufficient width to measure 500 µm 
from the lesion edge was placed on the image; then measures at 10 equally distanced points 
along rectangle length were taken. The ten points which marked the beginning of optical 
density profiles were generated using ImageJ software and extended 500 microns 
perpendicularly into the culture (figure 16).  
 
Figure 16: Optical density analysis in GFAP+ cultures  
A: Representative fluorescent micrograph of GFAP+ cultures 1 day post-lesion. A 
superimposed rectangle (aligned with lesion edge) of sufficient width to measure 500 µm 
from lesion edge was placed on the image; then measures at 10 equally distanced points 
along rectangle length were taken. Here, parallel lines extending 500 microns into the culture 
measured the optical densities across the length of the line. Optical density values were 
obtained along each of the indicated red lines, and also within unstained regions of the 
lesion, to provide background values. Scale bar: 100 microns. 
 
The ten measurements were averaged to form a single profile for each lesion, for 3 separate 
litters. Within each lesion, an area devoid of staining was identified and measured to give 
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background optical density values. A single corrected optical density profile from the 
astrocytic edge of each lesion was produced by subtracting the background optical density 
values. 
For DuraGen PlusTM treated experiments, P1-P3 mice derived micro-mixed glial cultures, 
were lesioned and had DuraGen PlusTM implanted after 15 days in vitro were fixed in 4% 
PFA at 1 and 7 days post-lesion and stained for GFAP and DAPI treated experiments. Low 
magnification x100 GFAP images of the lesion edge were obtained and converted to 
grayscale. Only the astrocytes in direct contact with the biomaterial were analysed and 
deemed useable. This was determined by DAPI-GFAP double merged images, here the 
DAPI was able to highlight the location of the DuraGen PlusTM insert (figure 22e, figure 28 
b/d). A superimposed rectangle (aligned with lesion edge) of sufficient width to measure 500 
µm from lesion edge was placed on the image; then measures at 10 equally distanced points 
along rectangle length were taken. The ten measurements were averaged to form a single 
profile for each lesion which was then averaged across lesions from 3 separate litters. A 
separate region within each lesion devoid of staining was identified to give background 
optical density staining. A single corrected optical density profile from the astrocytic edge of 
each lesion was produced by subtracting the background optical density values.  
For controls, P1-P3 mice derived micro-mixed glial cultures, were fixed in 4% PFA at day 15 
and day 21 in vitro and stained for GFAP and DAPI. Low magnification x100 GFAP images 
were taken from 3 random fields and converted to grayscale images. The middle of the 
image was determined, and the height of the image measured and divided by ten providing 
points which marked the beginning of optical density profiles and extended 500 microns 
perpendicularly into the culture. The ten measurements were averaged to form a single 
profile for each lesion which was then averaged across lesions from 3 separate litters.  
To quantify the optical density fold change, the single optical density values were grouped in 
distance away from the astrocytic edge 0-100 microns, 101-200 microns, 201-300 microns 
301-400 microns, 401-500 microns. The optical density fold change was then calculated by 
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dividing the optical density value at 401-500 microns away from the astrocytic edge in each 
image by all of the other data groups per experiment. For controls all group values were 
divided by the control 401-500 microns values. This was done to normalise the optical 
density fold change measurements taking microscope exposure settings out of the equation, 
each image thus acting as its own control. Quantification was carried out using ImageJ 
analysis software (NIH USA).  
2.5.4 Directionality analyses  
To characterize the palisading astrocytic morphologies seen at the lesion edge in response 
to injury, the directionality analysis on ImageJ was attempted. This analysis is used to infer 
the orientation of structures present in an image. Images without any orientation are 
expected to give a flat graph with no peaks, whereas a greater proportion of features sharing 
an orientation will produce a peak at that orientation. For example, in figure 17 the image on 
the right of the leaf displays projections in two main orientations; the leaf blades in the 
direction ca 60o and -60o. The corresponding histogram on the left displays this by showing a 
double peak curved graph with a peak at these angles and thus indicating that this image 
has directionality.  
 
Figure 17: The principles of the directionality analysis 
A histogram displaying the preferred orientation of the input image. Note how the leaf has 
projections ca 60oand -600, which is displayed as two peaks on the histogram on the left. 
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Thus, given that astrocytes in Model 1 displayed palisading morphologies with long thin 
processes, this methodology was used to characterize such responses. 
During 2.4.3, the same grayscale converted fluorescent GFAP micrographs were analysed 
for directionality. Here, the directionality was assessed in peri-lesional astrocytes (0-100 
microns away from the astrocytic edge) and distal astrocytes (401-500 microns away from 
the astrocytic edge). Since the lesions were often imaged at an angle (figure 12a), the 
images were rotated to make the lesion straight at 0o and a standard sized 100-micron wide 
box was placed in the peri-lesional area and distal area. For biomaterial treated coverslips 
only astrocytes associated with the biomaterial was analysed. This was determined by DAPI-
GFAP double merged images, where the DAPI was able to highlight the DuraGen PlusTM 
location (figure 22e, figure 28b/d). The directionality plugin on ImageJ was then used to 
generate a graph. The data per experimental condition was averaged across 3 litters to 
generate a single graph of directionality per experimental condition.  
2.5.5 Cell infiltration into the lesion/biomaterial per unit area  
P1-P3 mice derived micro-mixed glial cultures, lesioned after 15 days in vitro were fixed in 
4% PFA at 1 and 7 days post-lesion and stained for Iba1, NG2 and DAPI. Low magnification 
x100 images of the lesion were obtained and the numbers of Iba1+/ NG2+ cells were counted 
(only when immunostaining was clearly associated with DAPI staining) within each lesion 
using a standard size grid overlaid onto each image. The total number of Iba1+/ NG2+ cells 
per unit area were then averaged at each time point.  
For DuraGen PlusTM, treated experiments, P1-P3 mice derived micro-mixed glial cultures, 
were lesioned and had DuraGen PlusTM implanted after 15 days in vitro were fixed in 4% 
PFA at 1 and 7 days post-lesion and stained for Iba1, NG2 and DAPI. Low magnification 
x100 images of the DuraGen PlusTM were obtained and the numbers of Iba1+/ NG2+ cells 
were counted (only when immunostaining was clearly associated with DAPI staining) within 
each biomaterial. The total area of the DuraGen PlusTM was measured by drawing around 
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the biomaterial and used to generate the total number of Iba1+/ NG2+ cells per unit area, 
which was then averaged at each time point. Quantification was carried out using ImageJ 
analysis software (NIH USA). 
2.5.6 Microglial and OPC morphological analyses  
During analyses described in 2.4.5, as cells were counted, they were semi-quantitatively 
grouped for lesion only coverslips as either ramified (1 process or more) or amoeboid (no 
processes), the same criteria was applied for biomaterial treated coverslips (figure 30a-b 
insets). For lesion only coverslips OPCs were classified as ramified (3 or more processes) or 
bipolar/unipolar/unprocessed (2 processes or less) (figure 33a-b insets). The total number 
of cells with a morphological characteristic was then averaged at each time point. 
2.5.7 Statistical analysis 
GraphPad Prism v5.0 was used for all the statistical analyses performed. All quoted values 
are expressed as mean ± standard error of the mean (SEM) unless stated otherwise. Data 
was analysed by a one-way analysis of variance (ANOVA) with Tukey’s post-hoc analysis. In 
all cases, the number of experiments (n) refers to the number of individual cultures derived 
from separate mice litters. 
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Chapter 3 
Establishing a technical method to develop an 
in vitro multi-glial TBI model to evaluate 
cellular responses to biomaterial implantation 
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3.1 Introduction  
Currently, the evaluation of hydrogel-based regenerative strategies is reliant on live in vivo 
animal TBI models (126). These models have considerable limitations (see section 1.5.1) 
(143). Pathomimetic in vitro TBI model alternatives, allow  key biomaterials to be identified, 
whilst also preventing unnecessary animal experimentation and wasting valuable resources 
directly testing in vivo; an initiative in line with the Reduction, Replacement and Refinement 
of animal experimentation (the 3R’s principles) (see  section 1.5.6) (154). 
An ideal in vitro TBI model used to assess biomaterial based regenerative strategies must 
be: (i) neuropathomimetic to TBI (ii) capable of supporting biomaterial implantation into lesion 
sites (iii) facile (iv) high throughput. Currently, there is no such in vitro TBI model, hence this 
chapter aims to establish this model. 
In order to develop this model, a variety of in vitro culture systems could potentially be used. 
Organotypic slice cultures as pTBI models have previously been described in detail (see 
section 1.5.4). These models are neuromimetic and have been used to test biomaterials in 
vitro. However, as they are technically challenging and moderate throughput, such models 
are not widely accessible. On the other hand, whilst immortalized cell line-based models are 
high throughput and facile (see section 1.5.5) these models are unreliable due to the risk of 
cryptic contamination and resistance to cell death (140,146). 
Primary cultures from dissociated brain tissue have been used as high throughput TBI 
models. A variety of models with differing injury mechanisms exist; transection, compression, 
barotrauma, acceleration/deceleration induced neurotrauma, hydrodynamic models and cell-
stretch models. However, in the context of pTBI only transection models can simulate distinct 
areas of lesion “representative” of in vivo pTBI models (140). Furthermore, to assess the 
regenerative potential of biomaterials, a distinct lesion is essential to allow effective 
biomaterial implantation into the lesion sites, replicating current in vivo biomaterial testing. 
In vitro transection models involve lesioning confluent cultures with objects such as plastic 
pipettes, stylets and blades. Although, these models contain distinct lesion sites, they have 
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not yet been adapted to support biomaterial implantation. The advantages and 
disadvantages of these models is required to understand which models are suitable for 
biomaterial implantation.   
Previously, researchers have lesioned confluent astrocytic monocultures to mimic pTBI 
pathology (147). However, these models are not neuromimetic, specifically the lack of a 
microglial component means these models lack the primary immunocompetent immune cell 
of the CNS, which drives glial scar formation (64). More complex in vitro pTBI transection 
models include neural co-culture systems. Here, bulk cultures/cell lines are used to derive 
isolated neural cell populations, which are reseeded into 24 well plates. Astrocytes are most-
commonly cultured with microglia and neurons (155). Furthermore, neurons and glial cells 
have also been co-cultured (155). There are considerable disadvantages with such co-
culturing methodologies however; neural cell populations in different bulk cultures are often 
not cultured together in the same kind of media throughout the same experiment, which can 
influence cellular protein expression and behaviour (156). In addition, establishing 
stoichiometrically defined cell ratios in these models for reproducible and characterizable 
models is lengthy, and non-facile. In an attempt to exclude the effects of differing 
media/culture formats, researchers have grown mouse cortices as neurospheres and seeded 
single cells directly onto glass coverslips which differentiate into neurons, astrocytes and 
oligodendrocytes after 8 days (156). Although such a result shows promise, the lack of a 
microglial cell population is a limitation of this model. Thus, primary cultures which contain all 
of the glial cells need to be investigated for such application. 
The mixed-glial culture system, originally developed by Mccarthy and de Vellis, over 3 
decades ago, has been cited in more than 2,500 research papers (153). This protocol is 
widely used to derive individual glial cell populations from a bulk culture. Here, dissociated 
cortices are seeded into culture flasks and astrocytes form a confluent bed layer with 
microglial and OPC cells appearing on top. Once confluent, sequential shaking on rotary 
shakers can be used to derive high purity isolated glial cell populations. The original 
Mccarthy and de Vellis protocol derived cultures from rat brains, recently Schlidge et al 2013 
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has proven mice brain derived cultures also stratify in the same way and can be used to 
derive high purity isolated glial cell populations (157). Furthermore, mice cultures are 
considerably more economical to procure, maintain and house. Secondly, the ability to use 
transgenic/knockout mice provides increased experimental possibilities versus rat cultures.  
As a mouse mixed-glial culture contains all of the glial cell types which are the main 
determinants of responses to biomaterials and injury (see section 1.5.5), this chapter aims to 
adapt this mixed-glial culture into a micro-well format and introduce a lesion capable of 
supporting biomaterial implantation. Perhaps one disadvantage of such a model is that the 
lack of a neuronal component means axotomy and neuronal mediated microglial/astrocytic 
responses cannot be simulated. Thus, this chapter also intends to develop a high throughput 
primary culture system which contains all of the neural cell types: i.e. incorporating neurons.  
3.1.1 Identifying a suitable biomaterial to implant into lesions to assess regenerative 
strategies 
Collagen hydrogel matrices have been shown to provide therapeutic benefits in pTBI (see 
section 1.4.4). The major disadvantages of current studies, however, is that predominantly 
laboratory grade hydrogels unapproved for human use have been investigated. DuraGen 
PlusTM, is a clinically approved collagen hydrogel and has been discussed in detail in section 
1.4.5. Early studies have shown that DuraGen PlusTM is a biomimetic matrix, which supports 
the survival of neural cells, as well as possessing neuroprotective and neuroregenerative 
properties (128,129). Currently, there is no study which has investigated the regenerative 
potential of DuraGen PlusTM in pTBI and thus provides a novel objective.  
3.1.2 Current methods to visualize collagen biomaterials in the CNS following 
biomaterial implantation 
Distinguishing collagen biomaterials from surrounding tissue in vivo is challenging. Thus, 
researchers often have to rely on post-mortem analysis to determine the location of the 
biomaterials (113,114). In vitro models allow continuous biomaterial monitoring and can allow 
researchers to determine live cell-biomaterial interactions.  
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Polarizing light microscopy has been previously used to visualize the collagen within tissue 
sections (158). The dense network of parallel collagen fibres allows birefringence to be 
detected under polarizing light microscopy, thus this could be a useful tool to detect collagen 
biomaterials. Although fluorescent ICC forms a staple in visualizing cells, there are 
considerable disadvantages as when compared to histological methods of staining: samples 
tend to fade over time and require careful storage in dark and cool conditions. Secondly, 
fluorescent microscopes tend to be costly and may not be accessible to laboratories in 
poorer countries with limited resources and funding, whilst light microscopes are 
considerably cheaper. Picrosirius red is an example of a popular histological stain which has 
been used to stain collagen within tissue sections (159). In addition, studies have also 
demonstrated the efficacy of picrosirius red in staining collagen hydrogels (159). However, 
currently there are no protocols which enable researchers to double histological stain for both 
biomaterials and cells to study cell-biomaterial interactions, thus providing a novel aim for 
this chapter. There are considerable foreseeable challenges with such a protocol; histological 
stains such as picrosirius red, typically involve protocols which involve incubating the stains 
with samples for extended periods followed by acid washes, dehydration and subsequent 
mounting. Whilst such protocols are suitable for robust and durable tissue sections, they may 
be too harsh for cellular application. Secondly, a histological stain must either stain the 
cells/biomaterial only, but not both, so cells and biomaterial can be distinguished based on 
colour.   
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3.2 Objectives  
I. Determine if the mixed-glial culture model can be utilized in a micro-well (24 well 
plate) format to develop an in vitro model containing the major glial cell types: 
astrocytes, microglia and OPCs (Model 1). 
II. Establish a traumatic penetrating injury paradigm in Model 1.   
III. Establish a protocol for implanting a DuraGen PlusTM sheet into the lesion site. 
IV. Establish a double histological staining protocol whereby neural cells and 
DuraGen PlusTM can be distinguished based on colour using simple light 
microscopy. 
V. Conduct a pilot study to develop a model containing neurons and the major glial 
cell types (Model 2). 
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3.3 Experimental procedures    
Quantification methodologies for chapters 3 and 4 are set out under Materials and Methods: 
section 2.5 
3.3.1 Reagents and equipment 
 All reagents and equipment are listed in section 2.1. 
3.3.2 Development of a double histological staining protocol to distinguish neural 
cells and DuraGen PlusTM under light microscopy  
3.3.3 Polarizing light microscopy to study DuraGen Plus TM 
A pre-prepared piece of DuraGen PlusTM (section 2.3.4) was imaged under a polarizing 
light microscope (section 2.4.2) to determine if the biomaterial construct displayed 
birefringence. Here, the DuraGen PlusTM was placed under the microscope and imaged 
without the use of the polarizer i.e. simple light microscopy. To determine birefringence, 
counterpart images were taken of the DuraGen PlusTM when the polarizer was rotated. 
3.3.4 H&E staining of cells 
To determine whether the common histological stains H&E are suitable for a double 
histological cell-biomaterial staining protocol, each stain in turn was added to a pre-
prepared piece of DuraGen PlusTM (section 2.3.4) to determine whether these histological 
stains do NOT stain DuraGen PlusTM and thus suitable for this protocol. 
A plastic Pasteur was used to add a single drop off haematoxylin (10mg/ml) onto the 
DuraGen PlusTM for 30 seconds. Tap water was added to cover the DuraGen PlusTM for 1 
minute and discarded. 0.3% acetic acid ethanol was added for 1 minute and discarded. 
Tap water was added for 1 minute and discarded. 70% ethanol was added for a further 1 
minute discarded. 90% ethanol was added and discarded. Finally, the DuraGen PlusTM 
was mounted in Dibutylpthalate Polystyrene Xylene (DPX) onto a glass coverslip on a 
glass slide. Images of the DuraGen PlusTM were taken on a light microscope (section 
2.4.1) to determine whether haematoxylin had stained the biomaterial.  
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A plastic Pasteur was used to add a single drop of eosin (0.25% eosin Y) onto the 
DuraGen PlusTM for 30 seconds. 90% ethanol was added to cover the DuraGen PlusTM for 
1 minute and discarded. Likewise, 100% ethanol was added to cover the DuraGen PlusTM 
for 1 minute and discarded. Xylene was added for 2 minutes and the DuraGen PlusTM was 
subsequently mounted in DPX onto a glass coverslip on a glass slide. Images of DuraGen 
PlusTM were taken on a light microscope (section 2.4.1) to determine whether eosin 
stained the biomaterial.  
3.3.5 The cell-biomaterial double histological staining protocol 
To distinguish cells and biomaterials in differing coloured stains, a double histological 
staining protocol was developed. Here, fixed culture plates containing astrocytes were 
stained with GFAP-DAB to determine whether astrocytes could be immunolabelled. To 
determine whether this protocol could be combined with the collagen dye picrosirius red 
(PS red), fixed 7 days post-lesion biomaterial implanted cultures underwent the following 
protocol: 
The sample was incubated with 5% NDS-0.3%Triton X100 PBS blocker for 30 minutes.  
The solution was removed and 1:500 GFAP in 5% NDS-0.3%Triton X100 PBS blocker 
was added and placed in a 4oc fridge overnight. The solution was discarded, and the 
samples washed 3x in PBS (5 minutes/wash). The PBS was removed, and the samples 
incubated with 1:200 secondary biotinylated antibody in 5% NDS-0.3%Triton X100 PBS 
blocker for 2 hours. The solution was discarded, and the samples washed 3x in PBS (5 
minutes/wash). The VECTASTAIN ABC© reagent was added for 30 minutes. The solution 
was discarded, and the samples washed 3x in PBS (5 minutes/wash). The peroxidase 
substrate (1:500 DAB diluted into PBS with either 1:1000 0.3% hydrogen peroxide (brown 
deposits) or 1:1000 nickel (black deposits) was added under a fume hood and the 
samples are brought immediately to a light microscope (section 2.4.1). As soon as the 
peroxidase/nickel label was added, the astrocytes began to change colour immediately 
and thus after ten minutes when the astrocytes had completely stained through the 
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peroxidase substrate was removed, and the samples washed 3x in tap water. A plastic 
Pasteur pipette was used to submerge the sample in picrosirius red 0.1% for 5 minutes. 
The solution was discarded, and the samples washed 3x in PBS (5 minutes/wash). Please 
note that traditionally, acetic acid 0.5% is used to wash off PS red solution. However, it 
was noted that PBS was effective and had less risk of damaging the delicate adhered 
cells on the glass coverslips. The samples were mounted (section 2.2.4) onto a glass 
coverslip and imaged under a light microscope (section 2.4.1). A combination of low 
magnification and high magnification images were obtained to display whether this 
protocol successfully labelled cells and biomaterial in contrasting colours (figure 18). 
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                                 Figure 18: A schematic showing the DAB-PS red protocol
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3.4 Results 
3.4.1 Mixed-glial cultures show similar stratification in bulk and micro-well formats 
Mixed-glial cultures established in micro-well (micro-mixed glial) formats developed and 
stratified similar to bulk (macro-mixed glial) formats (figure 19). Across both formats the cells 
suspension adhered to the culture plastics. Within the first 2 days, the cultures recovered 
from the dissection process and numerous rounded cells with no distinct identifiable glial cell 
morphologies were present (figure 19a). From days 3 onwards, although some debris was 
still present, some cellular morphologies were now adherent. In addition, there were cells 
with astrocyte-like morphologies (figure 19b). From day 5, there were distinct colonies of 
cells with flat, polygonal, morphologies characteristic of astrocytes (figure 19c). Here, little 
cellular debris was seen surrounding these colonies as compared to the rest of the culture. 
At day 7 astrocyte like morphologies had proliferated and formed an astrocytic bed layer like 
morphology which increases in confluency (figure 19d-e). By day 14, there were cells with 
clear microglia like (phase bright cells with rounded/triangular cell bodies) and OPC-like 
morphologies (phase dark cells with bipolar/branched processes and oval cell bodies) on top 
of a confluent astrocytic bed layer like morphologies (figure 19f).   
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Macro-mixed glial culture 
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Micro-mixed glial culture 
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Figure 19: Phase contrast micrographs showed similar maturation and stratification of 
macro and micro-mixed glial cultures  
A: Representative phase contrast micrographs of days 0-2 in culture. The arrows show 
rounded cells and cellular debris with no distinct morphologies identifiable at this timepoint. 
B: Representative phase contrast micrographs of days 3-4 in culture. Cell debris was still 
present, but some cells were now adherent. The arrows show cells with astrocytic 
morphologies were evident. C: Representative phase contrast micrographs of days 5-7 in 
culture. The arrows show decreased cellular debris surrounding associated cell colonies. 
D/E: Representative phase contrast micrographs of days 7-12 in culture. The arrows show 
increasing confluency of astrocytic bed layer like morphologies (phase-dark flattened cells). 
F: Representative phase contrast micrographs of days 13-14 in culture. The culture was 
confluent. The arrows show OPC and microglial like morphologies can be identified on top of 
the astrocyte bed layer like morphologies. Scale bars: 100 microns. 
 
3.4.2 Lectin and A2B5 resulted in non-specific staining of the astrocytic bed layer  
To characterize the micro-mixed glial culture, lectin and A2B5 were initially used to 
immunolabel microglia and OPCs respectively. Both antibody stains were deemed 
unsuitable for use since lectin non-specifically punctate stained astrocytic bed layer like 
morphologies (figure 20a) whilst A2B5 stained cells with clear astrocyte like morphologies 
(figure 20b). Thus, lectin and A2B5 staining was discontinued, and Iba1/NG2 antibody 
stains were trialled (figure 20). 
 
 
 
 
 
77 
 
 
Figure 20: Lectin immunostaining resulted in artefacts while A2B5 staining was found 
to be non-specific  
A: Representative fluorescence micrographs of lectin+ cells. The white arrows show that 
these lectin+ cells displayed typical microglial morphologies. The red arrows show significant 
punctate staining of astrocytic bed layer like morphologies. B: Representative fluorescence 
micrographs of A2B5+ cells. The white arrows show non-specific staining of cells with clear 
astrocyte like morphologies. Scale bars: 100 microns. 
 
3.4.3 Astrocytes represented the predominant glial cell type in Model 1  
The micro-mixed glial cultures were characterized at day 14 to determine the presence of all 
of the glial cell types including their representative proportions within the cultures. The results 
showed that GFAP+ cells had consistent astrocytic morphologies which clearly formed a 
confluent astrocytic bed layer (figure 21a). Furthermore, Iba1+ cells showed consistent 
microglial morphologies and unlike lectin, did not result in punctate staining of the astrocytic 
bed layer (figure 21b). Similarly, NG2+ cells showed consistent OPC morphologies and 
unlike A2B5 did not label astrocytes (figure 21c). With regards to glial cell proportions within 
the cultures: astrocytes were found to be the most numerous glial cell type (82.6 ± 5.2%) 
whilst microglia (9.3 ± 3.6%) and OPCs (6.7 ± 2.1%) were present in smaller numbers and 
represented the minority glial cell types (figure 21d). 
 
 
78 
 
 
Figure 21: Characterisation of cellular composition in Model 1 at day 14  
A: Representative fluorescent micrographs of GFAP+ astrocytes at day 14. Here, astrocytes 
had formed a dense confluent astrocytic bed layer. B: Representative fluorescent 
micrographs of Iba1+ cells consistent with microglial morphologies. C: Representative 
fluorescent micrographs of NG2+ cells consistent with OPC morphologies. D: The graph 
shows the percentage of cells in the cultures at day 14. Here, astrocytes clearly represent 
the majority glial cell type. Scale bars: 100 microns, (n=4). 
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3.4.4 A reproducible and distinct penetrating lesion was introduced in Model 1  
A transecting lection was introduced into Model 1 according to the methods set out in 
section 2.3.3. At 0 hours post-lesion a reproducible and well-defined lesion was 
introduced (3.4.4) with very little cellular debris within the lesion (figure 22a-b). The lesion 
area was observed to be largely devoid of remnants of cell debris from the injury process 
(figure 22a-b). Furthermore, GFAP+ cultures demonstrated that a consistent and clear 
area negative for GFAP was consistent with the lesion (figure 22b). In addition, 
corresponding DAPI micrographs showed a distinct area devoid of nuclei consistent with 
the lesion (figure 22b). Furthermore, the astrocytic edges (lesion edges) could clearly be 
identified on either side of the lesion (figure 22a-b). The lesion width was measured 
according to the quantification methodology set out in section 2.5.2.  Briefly, 10 
measurements were obtained per-lesion, measuring the distance from one side of the 
astrocytic edge to the other. The average lesion width across all 4 cultures was 949 ± 26 
μm (Figure 22c). The average lesion widths from 4 independent cultures showed that the 
lesion protocol resulted in consistent, reproducible and defined lesions within the cultures.  
3.4.5 DuraGen PlusTM was successfully implanted into the lesion site 
Model 1 was adapted to support DuraGen PlusTM implantation into the lesion (figure 22d). 
At 2 hours post-lesion, a pre-prepared DuraGen PlusTM insert (section 2.3.5) was introduced 
into the lesion under microscopic guidance and imaged under light microscopy. Here, phase 
contrast images show that a DuraGen PlusTM sheet can be accurately placed abutting the 
lesion margins allowing for cell-biomaterial interactions to be imaged (figure 23d). Under 
phase microscopy the DuraGen PlusTM sheet appeared to be dark grey/black in colour in 
contrast to the light grey coloured lesion margins. After 7 days post-lesion DuraGen PlusTM 
showed a blue silhouette and can be accurately identified under the DAPI microscopic 
channel with clear nuclei identifiable within the DuraGen PlusTM at this timepoint (figure 22e). 
This indicated two things; DuraGen PlusTM inserts could be implanted into the lesion and 
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remained within the lesion until later time points. Secondly nuclei, within the DuraGen PlusTM 
indicated cellular infiltration into the biomaterial.   
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Figure 22: DuraGen PlusTM inserts were implanted into a well-defined lesion  
A: Representative phase micrograph showing a distinct lesion immediately after injury. B: 
Representative fluorescence GFAP+ micrograph of a lesion at 0 hours post-lesion. Note 
the lesion margin (top left), with relatively straight edges showing that a reliable and 
consistent lesion was introduced. Inset: Counterpart DAPI micrograph at 0 hours post-
lesion. Note the extremely limited amount of DAPI or GFAP staining between the lesion 
margins and lack of nuclei within the lesion. C: The graph shows that the lesion width 
across 4 independent cultures was consistent and thus reproducible lesions were 
introduced. D: The biomaterial was implanted into the lesion site 2 hours post-lesion. The 
arrows show that the biomaterial was placed abutting the lesion margin. E: 
Representative phase micrograph showing DAPI staining 7 days post biomaterial 
implantation. The white arrows show that the biomaterial remained in-situ, with nuclei 
within the biomaterial suggesting cellular infiltration into the biomaterial. Scale bars: A, D, 
E: 500 microns, B:300 microns, (n=10). 
 
3.4.6 DuraGen PlusTM did not show consistent birefringence under polarizing light 
microscopy  
To determine the suitability of polarizing light microscopy to detect birefringence in DuraGen 
PlusTM, the methodology in section 3.3.2 was followed. Under light microscopy, DuraGen 
PlusTM appeared to look dark grey with a mosaic like structure consistent with that of a 3D 
collagen biomaterial (figure 23a-b). Under polarizing light microscopy, it was evident that 
DuraGen PlusTM displayed small pockets of birefringence (figure 23a-b). On visual 
assessment only around 5% of the total biomaterial displayed birefringence and thus did not 
exhibit birefringence throughout, indicating that polarizing light microscopy cannot be used to 
detect the exact size and shape of the implanted DuraGen PlusTM (figure 23). 
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Figure 23: DuraGen PlusTM displayed minimal birefringence under polarizing light 
microscopy 
A/B: DuraGen PlusTM under light microscopy. C/D: Corresponding high magnification inset 
imaging showing areas of DuraGen PlusTM where birefringence was detected. Scale bars 
A/C: 100 microns, B/D: 25 microns. 
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3.4.7 H&E intensely stained DuraGen PlusTM  
H&E were trialled to determine whether these stains could be incorporated into a double 
histological cell-biomaterial stain. DuraGen PlusTM was intensely stained by both H&E (figure 
24a-b). Specifically, haematoxylin stained all the DuraGen Plus TM black/brown, with varying 
intensities of staining throughout different sections of the biomaterial (figure 24b). On the 
other hand, eosin produced consistent and diffuse red staining throughout the whole 
thickness of DuraGen PlusTM (figure 24a). This indicated that H&E would be unsuitable to 
use a stain to distinguish biomaterial from cells.  
 
Figure 24: H&E staining of DuraGen PlusTM  
A: Eosin stained DuraGen Plus
TM 
in a diffuse red/pink colour. B: Haematoxylin stained 
DuraGen Plus
TM
brown/black. Scale bars: 50 microns. 
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3.4.8 The double histological staining protocol distinguished astrocytes and DuraGen 
PlusTM under light microscopy 
The DAB-GFAP staining protocol was used to determine whether astrocytes could be 
effectively immunolabelled. Here, DAB-GFAP+ cells had clear astrocytic morphologies and 
appeared dark brown under light microscopy due to hydrogen peroxide deposits (figure 25a-
b). The DAB-PS red protocol was used determine whether DuraGen PlusTM and astrocytes 
could be co-immunolabelled. Here the confluent astrocytic bed layer was clearly labelled with 
black deposits (nickel) and could be seen in contrast to the diffuse and intensely red stained 
DuraGen PlusTM. The biomaterial was stained red/pink whilst cells were stained brown 
(hydrogen peroxide staining) or black (nickel staining) (figure 25c-d). Since this protocol 
successfully distinguished astrocytes and DuraGen PlusTM it was evident that at 7 days post-
lesion the astrocytes had infiltrated the biomaterial (figure 25c-d). Thus, the DAB-PS red 
protocol effectively distinguished biomaterial from cells.  
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Figure 25: Astrocytes and DuraGen PlusTM were distinguished via the DAB-PS red 
protocol  
A/B: Brown astrocytes labelled with GFAP-DAB and hydrogen peroxide. The cells were 
clearly stained and show morphologies associated with astrocytes. C/D: Black astrocytes 
(green arrows) labelled with GFAP-DAB and nickel contrast against the red stained (blue 
arrows) DuraGen PlusTM. Moreover, at 7 days post-lesion the astrocytes infiltrated the 
DuraGen PlusTM. A/B:  Scale bars: A/B: 25 microns, C: 100 microns, D: 40 microns. 
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3.4.9 Pilot data indicated that Model 2 contained all the major neural cell types 
The development of an in vitro model containing all of the neural cell types was attempted by 
establishing mixed-glial cultures in neuronal medium. The pilot data showed that Tuj1 could 
be used to label neurons within the culture. Two neuronal morphologies were seen; classical 
long processed neurons (figure 26a, white arrows) and rounded/clumped neurons (figure 
26a, green arrows). Iba1+ cells were consistent with microglial morphologies. Similarly, 
GFAP+ cells were consistent with astrocyte morphologies. In contrast with Model 1 a 
confluent astrocytic bed layer was not formed. Also, NG2+ cells had morphologies consistent 
with ramified OPCs. On visual assessment it was deemed that the percentage of cell types 
represented was approximately: neurons 30% (figure 26a), astrocytes 60% (figure 26c), 
microglia 5% (figure 26b), OPCs 5% (figure 26d) of cells within the culture. 
Note: The preliminary evidence supporting the development of Model 2 is provided above. 
Due to the COVID-19 pandemic and subsequent university shutdown, further datasets could 
not be generated to validate this finding.   
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Figure 26: Neuronal medium supported the growth of all neural cell types 
A-D: Representative fluorescence micrographs showing the presence of Tuj1+cells 
consistent with neuronal morphologies. Note how both rounded (green arrows) and 
processed neurons (white arrows) were present. B: Representative fluorescence 
micrographs showing the presence of Iba1+ cells consistent with microglial morphologies. C: 
Representative fluorescence micrographs showing the presence of GFAP+ cells consistent 
with astrocyte morphologies. Note how the astrocytes were not confluent in this culture. D: 
Representative fluorescence micrograph showing NG2+cells consistent with ramified OPC 
morphologies. Scale bars: A, B, D: 50 microns, C: 150 microns. (Pilot data, n=1). 
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3.5 Discussion  
3.5.1 Successful establishment of a high throughput, multi-glial, in vitro pTBI model 
I have developed a novel, high throughput, in vitro injury model capable of supporting 
implantation of a clinical grade biomaterial into the lesion site, to evaluate cell-biomaterial 
interactions. As discussed previously, current in vitro models typically use simplistic 
monocultures containing one glial cell type. This study modifies the original and widely used 
mixed-glial protocol to culture cells in a micro-well format, allowing high throughput studies 
on all the glial cell types together, rather than deriving high purity fractions of each individual 
cell type.  
Model 1 develops and stratifies in a very similar manner to the traditional bulk mixed-glial 
culture. Consistent with previous studies utilising bulk mixed-glial cultures, I found that in 
Model 1, astrocytes formed a confluent bed layer and represented the majority cell type 
(>80%) within the culture, followed by microglia and OPCs (153,157). Interestingly, 
astrocytes also represent the largest population of glia in the CNS, thus indicating that Model 
1is neuromimetic with respect to astrocytic representation (160).  
With regards to immunolabelling of cells, GFAP, Iba1 and NG2 was successful in labelling 
astrocytes, microglia and OPCs respectively. Iba1 was chosen preferentially to lectin as 
lectin seemed to have non-specific, punctate staining of the astrocytic bed layer making it 
difficult to identify microglia based on the immunostaining alone. Similarly, NG2 was used in 
preference to A2B5, since A2B5 non-specifically stained all of the cells within the culture, 
including cells which had clear astrocyte like morphologies. Chen et al (2007) mentions that 
mouse OPCs do not share all of the cell surface antigens with their rat counterparts such as 
A2B5 and thus could provide an explanation for this unexpected finding (161).   
In addition to this model being high throughput, this model is also facile versus current 
astrocytic monocultures/neural co-cultures. Simplistic astrocytic monoculture models can 
take 3-4 weeks to develop, since bulk mixed-glial cultures need to be established prior to 
isolation and re-seeding of astrocytes (147). In this study, Model 1 is fully confluent and 
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stratified by day 14. Model 1 is also seeded at a low seeding density of 0.83 x 105 cells/ml 
whilst the astrocytic monoculture models are seeded at high seeding densities (>4 x 105 
cells/ml), essentially meaning more tissue is needed to generate the same number of 
coverslips per culture, thus making such models lower throughput overall (147,157).  
Furthermore, Model 1 can be processed for live-cell imaging to allow real-time cellular 
responses to injury and biomaterials in addition to high resolution electron microscopy. I have 
previously noted that Model 1 can survive up to 38 days in vitro. One criticism of Model 1 is 
that post-natal tissue tends to be more plastic and pro-regeneration versus adult CNS, thus 
introducing lesions within the cultures at later time points may provide responses more 
representative of the adult CNS. Also, Model 1 provides an ideal platform to add additional 
immune cell types such as peripheral macrophages (56,81,162–165). Like microglia, 
peripheral macrophages also respond to injury and infiltrate the lesion core of the glial scar. 
In addition, like microglia, evidence suggests that peripheral macrophages may be beneficial 
for repair and regeneration post-injury. Thus, adding peripheral macrophages makes Model 1 
more neuropathomimetic to in vivo pTBI responses.  
3.5.2 A reproducible lesion was introduced into Model 1 
I have shown that a transection lesion which mimics the lesion track in pTBI can be 
introduced in a reliable and facile format. Specifically, I report similar and consistent lesion 
widths across 4 independent cultures. Researchers have previously used transection 
methods in in vitro models to mimic in vivo pTBI injury (140). The pipette tip induced lesions 
in this model resulted in lesions with little remaining intra-lesional cellular debris, and clearly 
identifiable astrocytic edges. Furthermore, unlike needle/scalpel based lesioning techniques, 
our lesion did not scratch the glass coverslip. This is an important consideration since glass 
fragments could influence glial responses whilst the depth and consistency of the scratch 
could alter the lesion environment along the length of the scratch which could elicit different 
glial responses. 
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3.5.3 Biomaterial implantation capabilities in Model 1 
To the best of our knowledge, this is the first time an in vitro pTBI model has been adapted to 
support biomaterial implantation into the lesion within a micro-well format. This chapter has 
demonstrated a successful protocol for implanting DuraGen PlusTM – a neurosurgical grade 
biomaterial, within a described lesion. This protocol provides troubleshooting solutions to the 
inherent difficulties with such a concept i.e. ensuring DuraGen PlusTM remains within the 
lesion and does not drift upon addition of media. Although DuraGen PlusTM was selected to 
establish this protocol, additional biomaterials could also be implanted into the lesion to 
screen regenerative strategies. Furthermore, nanoparticles could be injected into the large, 
well-defined lesion in Model 1 and thus Model 1 could also be used to test the utility and 
neural cell responses to nanoparticle additions (section 5.1.2).  
3.5.4 Polarizing light microscopy is unsuitable to visualize DuraGen PlusTM 
Imaging of biomaterials can be challenging, especially within a biological environment, and 
represents a major challenge for the field of tissue engineering. Polarizing light microscopy 
has previously been successfully used to visualize collagen containing tissue sections (158). 
This study showed that DuraGen PlusTM would be unsuitable to visualize under polarizing 
microscopy due to the lack of consistent birefringence. Two possible explanations include:  
collagen biomaterials contain disorganized collagen fibres versus the organized parallel 
collagen fibres found in tissue sections, as a result only microenvironments containing 
pockets of parallel collagen fibres show birefringence as demonstrated in this study. This 
could be due to setting the collagen in a mould versus natural collagen production present 
within tissues. Secondly, generally tissue sections have a greater density of parallel collagen 
fibres versus the collagen fibres within DuraGen PlusTM and thus shows a more intense 
birefringence signal.  
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3.5.5 Successful development of a double histological staining protocol 
To the best of our knowledge, this is the first time a double histological staining protocol has 
been developed which stains cells and collagen biomaterials in different colours allowing 
clear and distinct visualization of cell-biomaterial responses. In order to develop this protocol 
common histological staining methods such as H&E were trialled and deemed unsuitable, 
due to biomaterial staining, thus meaning neither cells nor biomaterials can be distinguished 
based on colour alone. I have shown that the DAB-PS red protocol allows researchers to 
counterstain black/brown coloured cells with red coloured biomaterial. This novel protocol 
offers many advantages to current fluorescent microscopy methods; collagen-specific 
staining within the biomaterial provides definitive evidence for the presence of the biomaterial 
versus reliance on auto-fluorescence. In addition, biomaterials which can be histologically 
stained are cheaper to use, as they do not require specialized dark storage conditions and 
samples do not fade with time -a major dilemma with fluorescently labelled samples. 
Furthermore, this protocol is accessible to remote laboratories with basic facilities since 
because basic light microscopes can be used to image the cell-biomaterial interactions 
without the need for complex and expensive fluorescent microscopes. Also, this protocol can 
be modified to support the use of additional dyes and histological stains. Masson’s Trichome 
is a collagen dye which has been widely used to stain tissue sections previously, and thus 
could be used as a replacement/in addition to picrosirius red.  
CSPGs have previously been described (section 1.2.2) as regeneration inhibitors and are 
present within the glial scar, thus the identification and characterization of such molecules 
through staining could provide important clues about the glial scar within Model 1. Finally, 
Model 1 has the capability to study detailed cell-biomaterial interactions and microglial 
dependent biomaterial biodegradation through live in vitro imaging, a type of microscopy very 
difficult to utilize in vivo. Although sufficient data was not gathered to evidence this in the 
thesis due to the COVID-19 pandemic, I have taken the first steps to characterize these cell-
biomaterial interactions through time-lapse microscopy.  
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3.5.6 Promising evidence in favour of a complete neural cell pTBI model  
Perhaps one limitation of Model 1 is that the model lacks a neuronal component. This means 
that axotomy and subsequent glial responses to axonal damage cannot be simulated (the 
neuronal responses in pTBI has been discussed in detail 1.3.9). In light of this limitation, the 
first steps have been taken to develop a novel, facile, high throughput injury model which 
contains all of the major neural cell types. I have shown through a pilot experiment, that the 
mixed-glial culture system can be established by replacing the D10 medium with a neuronal 
medium, which supported cultures containing neurons, astrocytes, microglia and OPCs. 
Although the pilot results seem promising, further experiments and testing is required to 
replicate this finding and adapt the model to support both a lesion and the capability of 
biomaterial implantation into the lesion to assess regenerative strategies.   
  
 
 
93 
 
Chapter 4 
Characterizing injury responses in the 
micro-mixed glial injury model (Model 1)  
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4.1 Introduction  
Reactive gliosis is the main glial response to pTBI (see section 1.3.8) (61). Specifically, both 
reactive microgliosis and astrogliosis have key roles in glial scar formation. Researchers 
have previously characterised glial responses to traumatic injury through a range of differing 
methodologies. It is important to simulate some of these responses in order to assess the 
safety and efficacy of biomaterials intended to treat pTBI.   
4.1.1 Methodologies to quantify reactive microgliosis  
The glial scar has been described anatomically as two distinct zones; the lesion core and the 
astrocytic zone (46,65,68). To characterise reactive microgliosis, researchers have 
previously quantified microglial infiltration into the lesion (66). In addition, researchers have 
determined whether microglia show stereotypical signs of activation, i.e. amoeboid M1 
microglia (see section 1.3.4 for a detailed explanation of the different microglial activation 
states).   
Weightman et al (2014), characterized microglial infiltration into a transecting lesion in 
organotypic spinal cord slices by counting the number of lectin positive cells within the lesion 
site of each slice, using a standard size grid overlaid onto each image (143). The total 
number of microglia per unit area were then quantified at each time point. This methodology 
provides a facile, yet robust and reliable method to quantify microglial cell density in the 
lesion areas. Furthermore, Weightman et al found that microglia in the lesion displayed 
“activated morphologies”, which appeared to be consistent with amoeboid morphologies.  
Microglia further away from the lesion were ramified characteristic of unactivated 
morphologies, though these cell responses were not quantified.  
Williams et al (2007), determined inflammatory leukocyte infiltration into the lesion in a rat 
penetrating ballistic brain injury model through morphological H&E staining and it was noted 
that “large macrophage-like cells“were present. Furthermore, Williams et al, found that in 
response to injury, microglia became highly ramified and positive for OX-18 (68). In peri-
lesional areas, microglia exhibited “immunoreactive processes” and bushy morphologies.  
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There are considerable limitations with this study. Firstly H&E is a non-specific histological 
stain and thus the cells within the lesion cannot be accurately identified as microglia, perhaps 
ICC methods such as Iba1/lectin staining could have been used which would provide 
stronger evidence in favour of microglial infiltration. Secondly, in contrast to the current 
literature, Williams et al found that in response to injury microglia increased in ramification. 
Although this shows that microglial responses can vary according to culture type, and 
mechanism of injury, amoeboid immunoreactive microglia are typically associated with injury 
responses. Furthermore, both Weightman et al, and Williams et al did not quantify any 
morphological changes and thus definitive changes with any statistical significance cannot be 
determined.  
Cernak et al (2014), characterized reactive microgliosis in a mouse pTBI model through Iba1 
image densitometry (39). Here, the staining intensity per pixel is characterized. Such a 
methodology is limited, as one cannot determine whether any changes are due to changes in 
microglial number, shape or size, rather an overall readout of how bright an image is given. 
Thus, quantifying both the microglial number and morphology separately could provide 
stronger evidence of microgliosis.   
4.1.2 Methodologies to quantify reactive astrogliosis 
Resting and processed astrocytes respond to injury by undergoing reactive astrogliosis (62). 
Here, astrocytes become reactive and hypertrophic and upregulate intermediate filament 
proteins such as GFAP. Morphologically, palisading astrocytes have been considered as a 
hallmark of the glial scar. Here, astrocytes align and extend long thin processes towards the 
lesion, eventually the thin processes entangle. ICC and histological methods of staining 
typically show reactive astrocytes with increased staining intensity versus non-lesioned 
astrocytes. Currently, researchers aim to quantify the increased staining intensity through a 
variety of methodologies. 
Cernak et al (2014) characterized reactive astrogliosis in the peri-lesional area by quantifying 
the image densitometry of GFAP staining intensity across timepoints (1 day, 3 days and 7 
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days post-lesion). This methodology allows GFAP immunoreactivity to be measured across 
conditions and timepoints. There are considerable limitations however, with regards to 
determining the effect of GFAP immunoreactivity when the biomaterial is added; here cells 
contacting the biomaterial needs to be compared to distal cells not in contact with the 
biomaterial. As a result, the image densitometry methodology is unsuitable when quantifying 
the GFAP immunoreactivity change in responses to biomaterial addition.  
Weightman et al (2014) characterized reactive astrogliosis by determining GFAP optical 
density in organotypic spinal cord slices 0-350 microns away from the lesion edges (143). 
Optical density measures were then averaged and grouped for every 100 microns away from 
the lesion edge. The groups were then compared across conditions. The Weightman et al 
study provides a useful methodology to compare the change in GFAP immunoreactivity 
within each lesion. Furthermore, this methodology is useful for Model 1 since it determines 
whether biomaterial addition has any effect on GFAP immunoreactivity, since comparisons 
between the astrocytes at the edge of the lesion in contact with the biomaterial and distal 
astrocytes can be made.   
Furthermore, as mentioned previously in response to injury astrocytes undergo marked 
morphological changes. Most studies currently do not quantify these morphological changes, 
rather comment on the morphologies. For instance, Weightman et al noted that in the peri-
lesional area reactive astrogliosis was noted by astrocytes possessing hypertrophic soma 
and thick processes, whilst astrocytes distal to the lesion were found to have “normal 
polygonal” morphologies.  
Bardehle et al (2013) is one of the few studies which has quantified astrocytic morphologies 
in response to traumatic injury (70). Bardehle et al determined that in response to an in vivo 
stab injury, astrocytes within 300 microns of the stab wound became palisading astrocytes 
with polarizing astrocytic morphologies and marked process extension towards the lesion 
site. Thus, in order to quantify this response, astrocytic processes were measured and 
compared to the astrocytic processes at 0 days post lesion. Bardehele et al found processes 
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extended up to 111 microns in length and astrocytes at 3-5 days post-lesion had a 3-fold 
greater length of processes versus astrocytes at 0 days post-lesion. However, there are 
inherent difficulties when applying this methodology to Model 1. In Model 1, the dense 
network of extended intertwined astrocytic processes makes counting, drawing and 
measuring such cells on analysis platforms such as ImageJ challenging and inaccurate, as 
each process must be linked to the corresponding astrocytic soma. Thus, a more generalised 
form of analysis which provides data on the overall morphological astrocytic changes is 
required. 
4.1.3 Methodologies to quantify OPC responses to traumatic injury 
The lesion core of the glial scar primarily contains fibroblasts, microglia and OPCs (figure 6). 
Previous studies have demonstrated that much like microglia, OPCs become activated, 
proliferate and infiltrate the lesion and peri-lesional area (79,81,83). Specifically, 
oligodendrocytes are highly susceptible to neural damage and depend on OPC differentiation 
and maturation to replace lost oligodendrocytes. Thus, characterizing this infiltration is 
crucial. Hampton et al characterized OPC infiltration into the peri-lesional area in a cortical 
stab wound injury model (82). Here, NG2 positive cells were counted only where a cell body 
and nucleus could be identified. Cell counts were recorded in 0.01mm2 standardized 
squares, which were placed adjacent to the lesion core. Buffo et al determined OPC 
infiltration into the peri-lesional area of a cortical stab wound by counting the number of Olig2 
positive cells in a 200,000-micron2 standardised grid, placed at the edge of the lesion (83). 
The values were then then expressed as cells/mm2 to allow comparisons across 
experimental groups (83). The methodology described here is similar to the methodology 
used by Weightman et al to determine microglial infiltration and provides an unbiased 
method to characterize cellular infiltration.  
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4.2 Aims and objectives  
The establishment of novel, high throughput, multi-glial in vitro model capable of supporting 
biomaterial implantation has been described in chapter 3. This chapter aims to characterize 
the glial responses to injury/biomaterial implantation and determine whether such a model is 
pathomimetic to pTBI. The specific objectives for this chapter are as follows: 
I. Characterize the astrocytic, microglial and OPC responses to the lesion in Model 1. 
II. Characterize the astrocytic, microglial and OPC responses to the DuraGen PlusTM insert 
within the lesion site in Model 1. 
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4.3 Results 
4.3.1 Peri-lesional astrocytes upregulated GFAP immunoreactivity in response to 
injury 
It was anticipated that any upregulation of GFAP near the lesion would be evident as being 
elevated compared to more distal regions. GFAP immunoreactivity was measured in peri-
lesional astrocytes (astrocytes within the first 100 microns of the astrocytic edge) and more 
distal astrocytes (101-500 microns away from the astrocytic edge). All data were normalised 
to the values for 401-500 microns (this region is hereafter referred to as the ‘distal lesion 
astrocytes’), within the same micrograph, and so expressed as fold-change versus 401-500 
microns. Uninjured control cultures showed no significant differences in GFAP 
immunoreactivity across 10 adjacent 100 micron regions of the culture (no lesion is present, 
so no astrocytic edge exists; 0 microns is an arbitrary location), indicating that there is little 
variation in GFAP intensity across control cultures (figure 27a-b). In response to injury, this 
study found a significant difference in the GFAP immunoreactivity fold-change between peri-
lesional astrocytes at 1 day (1.58 ± 0.12 normalised optical density fold-change)  and 7 days 
post-lesion (1.69 ± 0.25 normalised optical density fold-change) than distal astrocytes at 
either timepoint (1.00 ± 0.00 normalised optical density fold-change ; 401-500 microns; 
figure 27c). Astrocytes at 101-200 microns, 201-300 microns, 301-400 microns away from 
the astrocytic edge at 1 and 7 days post-lesion also displayed a fold-change in GFAP 
immunoreactivity  versus distal astrocytes, but no statistical significance was found (p>0.05, 
one-way ANOVA with Tukey’s post-hoc analysis, n=3). 
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Figure 27: GFAP immunoreactivity was elevated at the astrocytic edge 
A-B: Representative fluorescence micrographs at 1 day and 7 day GFAP positive control 
cultures. C-D: Representative fluorescence micrographs of lesioned GFAP positive cultures 
at 1 day and 7 day post lesion. The arrows indicate the marked morphological changes and 
GFAP immunoreactivity difference at the astrocytic edge.  E: The graph shows that the fold 
change in normalised optical density is greater within 100 microns of the astrocytic edge, at 
both 1 day and 7 days post-lesion (versus 401-500 microns away from the astrocytic edge; 1 
day post-lesion: **p<0.01, 7 day post-lesion: *** p <0.001, one-way ANOVA with Tukey’s 
post-hoc analysis, n=3). Scale bars: 100 microns. 
 
4.3.2 DuraGen PlusTM implantation into the lesion did not attenuate scarring responses 
The fold-change in GFAP immunoreactivity between peri-lesional astrocytes and distal 
astrocytes in DuraGen PlusTM treated cultures was compared to the fold-change in lesion 
only cultures (figure 28e and figure 27e) to determine astrocytic responses to DuraGen 
PlusTM. Similar to the result described in 4.3.1, this study found a significant difference in 
GFAP immunoreactivity in DuraGen PlusTM treated astrocytes in the peri-lesional area at 1 
day (1.48 ± 0.13 normalised optical density fold-change) and 7 days (1.51 ± 0.23 normalised 
optical density fold-change) post-lesion versus distal lesional astrocytes (1.00 ± 0.00 
normalised optical density fold-change) (figure 28e). However, no significant difference in 
the fold-change GFAP immunoreactivity between peri-lesional astrocytes in lesion only 
cultures at 1 and 7 days post-lesion (1.58 ± 0.12 normalised optical density fold-change) / 
(1.69  ± 0.25 normalised optical density fold-change) and DuraGen PlusTM treated cultured at 
1 and 7 days post-lesion (1.48 ± 0.13 normalised optical density fold-change) / (1.51 ± 0.23 
normalised optical density fold-change), (p>0.05, one-way ANOVA with Tukey’s post-hoc 
analysis, n=3). This result indicated that DuraGen PlusTM implantation into the lesion neither 
attenuates nor aggravates astrocytic scarring responses. 
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Figure 28: DuraGen PlusTM interfacing astrocytes upregulated GFAP immunoreactivity 
at the astrocytic edge  
A-D:  Representative fluorescent micrographs showing DuraGen PlusTM treated lesions. The 
arrows indicate where the astrocytes have extended long processes and infiltrated the 
biomaterial. C/D: DAPI-GFAP double merged fluorescent micrographs provided to show 
DuraGen PlusTM location with respect to the astrocytic edge. E: The graph shows that the 
normalised fold-change in optical density is significant at both 1 day and 7 days post-lesion, 
between 0-100 microns away from the astrocytic edge and 401-500 microns away from the 
astrocytic edge (1 day post-lesion: *p<0.05, 7 days post-lesion: *p<0.05, one-way ANOVA 
with Tukey’s post-hoc analysis, n=3). Scale bars: 100 microns. 
 
4.3.3 Astrocytes responded to injury by extending aligned processes perpendicular to 
the lesion  
In response to injury astrocytes underwent marked morphological changes (figures 27c/d, 
figure 28c/d). Here astrocytes became hypertrophic and extended long processes towards 
the lesion/biomaterial indicating the formation of a palisading astrocytic zone. On visual 
assessment, astrocytes tended to extend long processes perpendicularly to the lesion. Due 
to the high density of intertwined processes, identifying and measuring individual astrocytic 
processes was deemed unreliable. Thus, a new form of analysis was attempted to determine 
whether the general astrocytic morphologies could be characterized (see section 2.5.4). The 
directionality analysis on ImageJ was used to determine whether astrocytes within an image 
displayed alignment. The images shown in figure 27c/d and figure 28a/c were analysed. 
The automated analysis plugin represents any alignment preference (directionality) by 
displaying a graph with peaks, the peak indicating the angle at which the alignment 
preference is identified. Whilst, no alignment preference (equal representation for every 
direction) is represented by a straight horizontal line with no peak. 
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Lesion only and biomaterial treated peri-lesional astrocytes were represented on the graph 
as a curve with a peak indicating an alignment preference, whereas distal lesional astrocytes 
were represented with a straight line indicating random alignment (figure 29a-d).  
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Figure 29: Images of peri-lesional astrocytes displayed an alignment preference 
towards the lesion versus images of distal astrocytes 
A-D: The graphs indicate that regardless of time-point and biomaterial addition, micrographs 
of astrocytes within the first 100 microns from the astrocytic edge display alignment which is 
indicated by a large peaked curve, whilst images of astrocytes 401-500 microns from the 
astrocytic edge display an even frequency across all orientations, and are represented by a 
straight line with no peak, (n=3). 
 
4.3.4 Microglia and OPCs infiltrated both the lesion and DuraGen PlusTM 
The number of microglia/OPCs per unit area was determined across time-points to determine 
whether these glial cell types infiltrated the lesion core in Model 1. Significantly greater 
numbers of microglia infiltrated the lesion core at 7 days post-lesion (82.04 ± 5.11 cells/mm2) 
than 1 day post-lesion (37.48 ± 7.54 cells/mm2; p<0.05, one-way ANOVA with Tukey’s post-
hoc analysis, n=3; figures 30a-b, figures32a). Similarly, significantly greater numbers of 
OPCs infiltrated the lesion core at 7 days post-lesion (45.72 ± 9.08 cells/mm2) than1 day 
post-lesion (1.65 ± 1.62 cells/mm2) than, p<0.05, one-way ANOVA with Tukey’s post-hoc 
analysis, n=3) (figure 34a-c).  
The number of microglia per unit area within the DuraGen PlusTM was also determined to 
allow comparisons with the numbers of cells/unit area within the lesion core in lesion only 
cultures. Significantly greater numbers of microglia infiltrated the DuraGen PlusTM at 7 days 
post-lesion (132.41 ± 15.83 cells/mm2) versus lesion only cultures at 7 days post-lesion 
(82.04 ± 5.11 cells/mm2), p<0.05, one-way ANOVA with Tukey’s post-hoc analysis, n=3) 
(figures 31a-d,figures 32a). Also, significantly more microglia infiltrated the DuraGen PlusTM 
at 7 days post-lesion (132.4 ± 15.83 cells/mm2) versus 1 day post-lesion (55.35 ± 17.44 
cells/mm2) (figures 31a-d, figures 32a, p<0.05, one-way ANOVA with Tukey’s post-hoc 
analysis, n=3). There was evidence to suggest that OPCs also infiltrated the DuraGen PlusTM 
and adopted rounded morphologies with very few processed cells (figure 34a-d). 
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4.3.5 Microglia predominately adopted amoeboid morphologies in the lesion and 
DuraGen PlusTM 
To determine microglial morphology within the lesion/DuraGen PlusTM microglia were 
classified as ramified or amoeboid (section 2.5.6). This study found that microglia infiltrating 
the lesion predominately had amoeboid morphologies at 1 day post-lesion (74.3 ± 5.5%) 
versus ramified morphologies (25.7 ± 5.5%) (figure 30a-b, figure 32a). Similarly, at 7 days 
post-lesion microglia predominately had amoeboid morphologies (70.3 ± 2.2%) versus 
ramified morphologies (29.7 ± 2.2%). Similarly, microglia predominately had amoeboid 
morphologies in the DuraGen PlusTM at 1 day post-lesion (79.8± 4.0%) versus ramified 
morphologies (20.2 ± 4.0%), (figure 31a-d, figure 32b), p<0.001, one-way ANOVA with 
Tukey’s post-hoc analysis test, n=3). At 7 days post-lesion microglia also predominately had 
amoeboid morphologies in the DuraGen PlusTM (76.4 ± 9.1%) versus ramified morphologies 
(23.6 ± 9.1%) (figure 31a-d, figure 32b), p<0.001, one-way ANOVA with Tukey’s post-hoc 
analysis test, n=3). 
4.3.6 OPCs adopted ramified morphologies in the lesion and evidence of rounded 
morphologies in DuraGen PlusTM 
On visual observation it was noted that the majority of OPCs seemed to have many 
processes within lesion only cultures, thus were classified as ramified (3 or more processes) 
or bipolar/unipolar/unprocessed (2 processes or less) (figure 33a-b). This study found that in 
lesion only cultures OPCs were predominately ramified (figure 33d) at both 1 day post lesion 
(79.6 ± 7.8%) and 7 days post-lesion (81.4 ± 5.4%), p<0.001, one-way ANOVA with Tukey’s 
post-hoc analysis test, n=3).  
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Figure 30: Increased microglia infiltrated the lesion core at 7 days post-lesions versus 
1 day post-lesion  
A: Representative fluorescence micrographs showing early evidence of microglial infiltration 
at 1 day post-lesion. B: Representative fluorescence micrographs showing increased 
microglial infiltration at 7 days post-lesion. Note the inset images show that microglia are 
predominately amoeboid in morphology (green arrow) versus ramified (white arrow). Scale 
bars: 500 microns. 
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Figure 31: Increased microglia infiltrated the DuraGen PlusTM 7 days post-lesion 
compared to 1 day post-lesion. 
A: Representative fluorescence micrographs showing early evidence of microglial infiltration 
into the DuraGen PlusTM at 1 day post-lesion. B: DAPI counterpart for A. C: Representative 
fluorescence micrographs showing increased microglial infiltration into the DuraGen PlusTM at 
7 days post-lesion. D: DAPI counterpart for C. Scale bars: 100 microns. 
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Figure 32: Iba1+cells infiltrated the lesion core and DuraGen PlusTM 
A: The graphs shows significantly more Iba1+ cells in lesion only cultures at 7 day post 
lesion versus  1 day post lesion. Furthermore, there were significantly more Iba1+ cells in the 
DuraGen PlusTM at 7 days post-lesion versus 1 days post-lesion. Finally, there were 
significantly greater Iba1+ cell infiltration into DuraGen PlusTM versus lesion infiltration at 7 
days post-lesion (*p<0.05; **p<0.01; one-way ANOVA with Tukey’s post-hoc analysis, n=3). 
B: The graph shows significantly more amoeboid Iba1+ cells in the lesion versus ramified at 
both 1 day and 7 days post-lesion. There were significantly more amoeboid cells in the 
DuraGen PlusTM insert at both 1 and 7 days post-lesion (***p<0.001, one-way ANOVA with 
Tukey’s post-hoc analysis, n=3). 
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Figure 33: Increased OPCs infiltrated the lesion core at 7 days post-lesion versus 1 
day post-lesion  
A: Representative fluorescence micrographs showing early evidence of OPC infiltration at 1 
day post-lesion. B: Representative fluorescence micrographs showing increased OPC 
infiltration at 7 days post-lesion. The corresponding inset images show examples of ramified 
(blue arrow) and bipolar (red arrow) OPC morphologies. C: The graphs show significantly 
more NG2+ cells within the lesion at 7 days post-lesion versus 1 day post-lesion. D: The 
graphs shows significantly more ramified cells in the lesion versus 
bipolar/unipolar/unprocessed cells in the lesion at both 1 and 7 days post-lesion. Scale bars: 
500 microns. (p-value for *** = p<0.001 unless otherwise stated, one-way ANOVA with 
Tukey’s post-hoc analysis, n=3). 
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Figure 34: OPCs infiltrated the DuraGen PlusTM and adopted rounded morphologies 
A: Representative fluorescence micrographs showing rounded OPC morphologies in the 
DuraGen PlusTM at 1 day post-lesion. B: DAPI counterpart for A. C: Representative 
fluorescence micrographs showing predominately rounded OPC morphologies (black arrows) 
in the DuraGen PlusTM  versus processed (red arrows) at 1 day post-lesion. D: DAPI 
counterpart for C. These images were deemed unsuitable for quantification, due to the 
difficulty in visualizing the cells. Scale bars: 75 microns. 
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4.4 Discussion  
I have developed a novel, facile, multi-glial injury model which can screen biomaterials for 
clinical applications. Experimental studies investigating regenerative strategies rely heavily 
on animal models, and biological replicates in double digit numbers are the norm. I consider 
that the in vitro Model 1 can contribute significantly to the Reduction and Refinement animal 
models. I have previously seeded mixed-glial cultures in 5 x 24 well plates at a concentration 
of 0.83 x 105 cells/ml derived from 8 P1-P3 mouse cortices, which became confluent by day 
14 and were ready to support lesions/biomaterial implantation. This means 60 different 
biomaterials can be screened and directly compared to one another at any one time (in 
addition to 60 lesion only control coverslips). Thus, Model 1 is high throughput and can be 
used to screen multiple biomaterials at the same time prior to in vivo testing. Interestingly, 
mixed-glial cultures have previously been derived from human brain tissue (166). However, 
like rodent models, these cultures have predominately been established in bulk culture 
format. Ray et al has successfully cultured a human-neuronal glia model in vitro in a micro-
well format (167). Here, neurons and glia could be observed from day 20 in vitro. Thus, like 
Model 1, human mixed-glial cultures have the potential to be established in a micro-well 
format. A human micro-mixed glial model has a major advantage; human cells, would 
provide a neuropathomimetic platform to human in vivo cellular responses. To develop the 
Ray et al model further, application of the lesion and biomaterial implantation protocols set 
out in this thesis could provide a human neuron-glia model to study the regenerative 
properties of relevant biomaterials. 
If Model 1 is demonstrated to be pathomimetic for features of pTBI, Model 1 will provide a 
first-line screening system for promising regenerative therapies prior to animal 
experimentation. This study showed that peri-lesional astrocytes upregulated GFAP as 
compared to distal astrocytes in response to a transecting lesion both 1 day and 7 days post-
lesioning. This finding is in-line with previous studies; GFAP upregulation in response to 
injury is considered a hallmark of the glial scar. The mouse pTBI model developed by Cernak 
et al (2014) showed that peak GFAP upregulation in response to injury was observed at 72 
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hours post-lesion with GFAP upregulation persisting 7 days post-injury (39). The finding of 
significantly increased GFAP upregulation at 1 days post-lesioning is expected from the 
literature on in vivo responses, as often cells react rapidly to injury. Specifically, the Williams 
et al rat pTBI model showed upregulated GFAP by 6 hours-post injury (68). The organotypic 
SCI model developed by Weightman and colleagues found significantly increased GFAP 
upregulation within the first 100 microns away from the lesion in response to transection, with 
fluorescent intensity measures decreasing as distance away from the lesion increases, a 
finding replicated by our study (143). The findings from the current study are therefore 
consistent with these observations.  
Due to the distinct palisading astrocytic morphologies, potentially the upregulated GFAP 
could be explained due to greater GFAP localization within the outstretched astrocytic 
processes, whilst the overall amount of GFAP within the astrocytes remains constant. Since 
the optical density of GFAP was measured across 500 microns into the culture from the 
lesion edge, such a phenomenon would have already been taken into account and would not 
yield a difference in the normalised optical density fold-change as seen in Model 1. 
Previously, studies have shown that astrocytes infiltrate biomaterials, and bridge the lesion 
(126). This study found that astrocytes infiltrated the DuraGen PlusTM and that there was no 
significant difference between the GFAP upregulation in peri-lesional astrocytes in lesion 
only and DuraGen PlusTM treated cultures. This indicated that DuraGen PlusTM neither 
disrupted nor aggravated glial scarring with respect to the astrocytic responses. Furthermore, 
this result showed that DuraGen PlusTM implantation into Model 1 did not damage the 
astrocytes and thus aggravate the reactive astrogliosis responses, providing evidence that 
the biomaterial implantation protocol is reliable. 
There was a concern that astrocytic GFAP upregulation could be due to the intralesional 
cells being displaced on top of the peri-lesional cells, thus falsely elevating GFAP. Although 
this may be of concern within other culture systems there is very little to no evidence to 
suggest that this is the case within Model 1. Firstly, on a glass coverslip, PDL helps to 
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adhere cells to the glass coverslip. Within Model 1 upon lesioning it would be extremely 
unlikely that the cells would be displaced onto the peri-lesional area and adhere on top of the 
cells. It is much more likely that the lesioned cells float within the medium and are removed 
during the medium replacement step. Secondly, it is clear from figure 27 C and D, that 
astrocytes have clear palisading morphologies in the peri-lesional area, whilst control cells do 
not adopt these morphologies. If the cells did displace, then one would expect control like 
morphologies with no palisading activation within the peri-leisonal area, however this is not 
seen. In addition, it is clear that GFAP is upregulated within the palisading astrocytic 
processes and is localized here. If cell displacement did occur, one would not expect 
palisading astrocytic morphologies and certainly not expect black gaps between well-defined 
GFAP positive astrocytic processes. Finally, from figure 22b  it is clear the numbers of nuclei 
at the edge of the lesion are similar throughout the coverslip (except within the lesion), thus if 
cells had displaced onto the lesion edge this would be associated with a greater 
concentration of DAPI positive nuclei accordingly.  
I have shown that in response to injury, astrocytes underwent significant morphological 
changes. In particular, hypertrophy of astrocyte soma, extension of astrocytic processes and 
astrocytic alignment perpendicularly to the lesion. These astrocytic responses are analogous 
to the palisading astrocytes which are considered a hallmark of the glial scar in vivo (70,71). 
This study found that the general palisading astrocytic responses seen in Model 1 can be 
represented and quantified through a directionality analysis. There are however considerable 
limitations with this methodology. Indeed, this protocol enables researchers to broadly 
characterize palisading astrocytes, however it cannot provide nor compare the lengths of 
astrocytic processes across experimental conditions. Furthermore, comparisons across 
experimental conditions such as with DuraGen PlusTM treated cultures cannot be made since 
the graphs simply indicate whether an alignment is detected. One solution to this, is to 
perhaps obtain TEM images, of the palisading astrocytes, here individual astrocytes should 
be identifiable and thus the measurements of astrocytic processes extension can be viewed 
in context with the directionality analysis allowing cross condition analysis.  
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I have shown that microglia infiltrated the lesion core, as early as 1 day post-lesion with 
significantly more microglia infiltration at 7 days post-lesion. Furthermore, significantly more 
microglia within the lesions were morphologically amoeboid versus ramified. This finding is in 
line with the current literature; Cernak et al that cortical microglia remained activated up to 7 
days post-injury, a finding replicated in a rat pTBI model, previously developed by Cernak 
and colleagues. Furthermore, Weightman et al (2014) found that microglia also infiltrated the 
lesion, with peak microglial levels detected at 5 days post-lesion and adopted amoeboid 
morphologies, a finding similar to ours. Evidence both for and against microglial infiltration 
into the lesion as an inhibitory step to regeneration exists in the current literature. Microglia 
have been implicated as inhibitors of axonal regeneration via the expression of inhibitory 
guidance molecules such as netrin-1 (143). However previous studies also indicate that initial 
microglial infiltration into the lesion helps to clear cellular debris which is inhibitory to axonal 
regeneration (15,53,65). Secondly, the microglial role in astrocytic activation has also been 
described as a key step in glial scar formation, preventing healthy cells to be exposed to 
inhibitory molecules and cellular debris within the lesion core (64). 
Also, I have demonstrated that significantly more microglia infiltrated the DuraGen Plus TM 
than the lesion after 7 days post-lesioning. Furthermore, in the DuraGen Plus TM the microglia 
predominately had amoeboid morphologies versus ramified. This result shows that DuraGen 
PlusTM an ultrapure, FDA approved biomaterial which is branded as biocompatible, 
biodegradable and minimally immunogenic, may not be as ‘minimally immunogenic’ as is 
claimed by the company. Currently, little is known whether transient microglia infiltration into 
biomaterials is beneficial or detrimental. It is postulated that microglial infiltration into 
biomaterials and subsequent enzymatic breakdown of the hydrogels influence 
biodegradability. However further research such as high-level gene profiling studies is 
needed to determine whether microglial infiltration into the DuraGen PlusTM is beneficial or 
detrimental to repair. 
I also demonstrated that OPCs infiltrated the lesion, with significantly more OPC infiltration 
7 days post lesion versus 1 day post-lesion and adopted. Our study showed that very few 
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OPCs were in the  lesion site at 1 day post-injury (81). This could potentially be explained 
by a loss in OPC number due to the toxic, acute lesion environment. In particular, 
proteolytic enzyme release from necrotic cells can damage cells. Furthermore, activated 
microglial release of free radicals, pro-inflammatory cytokines and glutamate has been 
shown to promote oligodendrocyte loss (81). Previously, studies have demonstrated that 
OPCs infiltrate the lesion and peri-lesional area, here OPCs can differentiate into 
oligodendrocytes to replaces dead cells (81). In addition, this study showed, that the cells 
in the lesion had ramified morphologies indicating that the lesion environment did not 
affect OPC maturation from 1 day post-lesion to 7 days post-lesion. The presence of 
OPCs in the biomaterial could be explained by OPCs preferentially migrating into a less 
toxic environment versus the lesion alone which contains some cellular debris. This may 
also be explained by a preference to infiltrate a softer biomaterial in comparison to a 
relatively hard glass coverslip. Interestingly, our study also showed that OPCs adopted  
rounded morphologies within the biomaterial. This is a surprising finding, however Russel 
et al previously demonstrated that OPCs incorporated into a PEG hydrogel adopted 
spheroid morphologies similar to the morphologies seen in this study and thus OPCs may 
be less likely to mature into oligodendrocytes within the DuraGen PlusTM than the lesion 
alone (168). One possible explanation is that DuraGen PlusTM is a relatively soft 
biomaterial. Previous studies have demonstrated that OPCs cultured inside soft hydrogels 
display “round morphologies with very few spreading processes” whilst OPCs on medium 
stiffness hydrogels resemble the processed OPCs seen within the host CNS (169). 
One possible limitation of this model is that the cells which have been associated as 
infiltrating the biomaterial, may be underneath it and thus there needs to be consideration to 
whether this model should be classified as a 2D or 3D model. With regards to biomaterial 
infiltration, it is also not possible to rule out that cells infiltrate underneath the biomaterial and 
then grow upwards into the biomaterial. DuraGen PlusTM is a 3D collagen matrix with a 
porous structure and thus supports bilateral cellular movement within the hydrogel. In 
addition, there is evidence both for and against classifying Model 1 as 3D. Firstly, the 
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astrocytes initially adhere to the coverslips and eventually become confluent with additional 
glial cell types including the microglia and OPCs eventually appearing on top of the astrocytic 
bed layer. Thus, based on this, the mixed-glial culture is multi-cellular and to some extent a 
3D culture system. Indeed, this model is not as 3D as organotypic brain slice cultures nor in 
vivo brain tissue, thus given these discrepancies further research and investigation is 
required determine whether this model is truly 3D.   
4.4.1 Model 1 replicates foreign body reactions to neural implants 
In addition, Model 1 could provide researchers with a novel, in vitro model to study the 
foreign body reaction to neural implants. The reactive gliosis and OPC responses seen in 
Model 1 allows this model to be used to study not only implants in the context of pTBI, but 
also the foreign body reaction to microelectrodes. Implantable microelectrodes have been 
used in the management of traumatic and neurodegenerative pathologies. However, 
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although this intervention shows promise, specifically the glial cell responses at the injury site 
to BBB dysfunction and neuronal death results in failure of the implant over time (figure 35). 
 
Figure 35: A schematic displaying how neural cell responses to microelectrodes 
correlates with subsequent electrode performance (170). 
Gulino et al mentions that in response to a foreign body, astrocytes extend long processes 
and upregulate GFAP, while microglia are acutely activated and are responsible for the 
secretion of pro-inflammatory cytokines, phagocytosis of cellular debris and 
astrocyte/oligodendrocyte cross talk (102,170). Oligodendrocyte cell death occurs at the 
implantation site, OPCs migrate towards the implant where they can differentiate into 
astrocytes. After 2 weeks, the glial scar matures, here astrocyte process extension contacts 
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the implant forming a non-permeable barrier (to cells) between the implant and tissue. 
Fibroblasts then secrete ECM proteins such as fibronectin, type IV collagen, laminin and 
CSPGs, further encapsulating the microelectrodes. This forms an “insulation” barrier which 
hampers electrophysiological performance due to the absence of contact between the 
electrode and neurons, thus leading to implant failure. Although Model 1 cannot replicate 
BBB dysfunction and neuronal death, the glial responses could be replicated. Early evidence 
indicates that Model 2 contains a neuronal component and thus could provide a more 
neuromimetic model, of greater value for testing electroactive biomaterials, especially those 
intended to stimulate neuronal cells. Furthermore, macrophages, fibroblasts and additional 
cell types can be added to Model 1 which in conjunction with the astrocytes could attenuate 
the formation of an insulation barrier to microelectrodes.  
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Chapter 5 
 Future direction and concluding comments  
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5.1 Summary of key thesis findings  
I have shown that Model 1 is a capable of supporting biomaterial implantation into lesion 
sites to assess regenerative strategies. Specifically, I have shown: 
• In response to injury peri-lesional astrocytes upregulate greater amounts of GFAP 
versus distal lesional astrocytes and that DuraGen PlusTM implantation did not 
significantly alter these responses.  
• Microglia infiltrate both the lesion and DuraGen PlusTM and appear to adopt amoeboid 
morphologies. 
• OPCs infiltrate the lesion core and early evidence of DuraGen PlusTM infiltration. 
• The development of a novel, double histological staining protocol, which enables 
researchers to visualize cell-biomaterial interactions through simple light microscopy. 
• The first steps have been taken to develop a neuronal model, which contains all of 
the neural cell types available in a micro-well format.   
5.1.2 The future direction for this research 
I have developed a protocol which enables researchers to implant biomaterials into a lesion 
within a micro-well format. Although, this study implanted DuraGen PlusTM, additional 
biomaterials could also be implanted and screened within the model. Furthermore, I found a 
novel and interesting finding: an FDA approved, neurosurgical grade biomaterial DuraGen 
Plus TM is preferentially infiltrated by the major immune cell type of the CNS; the microglia. 
This raises considerable questions specifically with regards to whether such biomaterials can 
be classified as immunogenic, minimally immunogenic or cytotoxic. Whether microglial 
infiltration was transient in nature or due to the immunogenic profile of DuraGen PlusTM, 
remains in question. In the future, detailed gene profiling and expression studies to 
determine whether the microglia inside the biomaterial upregulate or downregulate key 
immunological markers such as pro-inflammatory cytokines and select matrix 
metalloproteinases (45,60,103,171). Furthermore, this study could provide a model for 
detailed live in vitro biomaterial degradation and biodegradability studies, as it is likely that 
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biomaterial biodegradability profiling is subject to microglial infiltration and enzymatic 
breakdown of the biomaterials.  
Researchers have successfully transplanted neural cells in biomaterial constructs in animals 
to promote regeneration and repair in lesioned CNS (79,90,105). However, the majority of 
these studies, have tested laboratory grade and unapproved biomaterial constructs. Finch et 
al has shown that transplant populations such as NSC and astrocytes have high viability and 
retain their differentiation potential in DuraGen PlusTM. However, the viability of these cells 
was assessed in a non-injury environment. Thus, neural cell laden DuraGen PlusTM 
constructs could be implanted into Model 1 to determine whether the injury environment, and 
microglial infiltration into the biomaterial, affects transplant cell morphology and differentiation 
potentials, and thus whether such a concept could be considered for clinical translation. In 
addition, previously clinical -grade magnetic nanoparticles have been successfully 
incorporated within the neural transplant populations with biomaterial constructs (172). Non- 
invasive magnetic resonance imaging can then be used to track transplant populations. 
Model 1 could easily be adapted to test the uptake, toxicity and efficacy of nanoparticles. 
Furthermore, nanoparticle laden transplant populations could be incorporated within 
biomaterial matrices and implanted into the lesion in Model 1 to determine their functional 
efficacy. 
The pilot study in this thesis shows that a neuronal-glia model can be developed and 
requires further experiments to reproduce this finding. Furthermore, given the same 
experimental formats as Model 1, Model 2 could also be adapted to support a lesion and 
biomaterial implantation into lesion sites to assess regenerative strategies.  
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5.2 Concluding comment 
I have developed a novel, in vitro TBI model in which the regenerative potential of 
biomaterials can be assessed. This model could provide a higher throughput and more 
ethically viable platform to screen neuroregenerative therapies prior to in vivo animal 
experimentation enabling the identification of key regenerative biomaterials/strategies, with 
the ultimate aim of clinical translation.  
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